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Abstract
Iron is crucial for many cellular processes including DNA synthesis and respiration. The
majority of iron in mammals is in heme within hemoproteins, inside cells, or transported
through circulation by the glycoprotein transferrin, which constitutes the greatest iron source
in serum. Limiting iron availability is an important facet of nutritional immunity to help
prevent infection.
Staphylococcus lugdunensis is a human skin commensal and opportunistic pathogen
capable of causing a variety of infections, including particularly aggressive endocarditis. It is
an emerging pathogen with elevated virulence compared to other species of coagulasenegative staphylococci. The versatility of S. lugdunensis to infect multiple niches and cause
aggressive infection indicates that it likely adapts its cellular physiology to overcome host
defenses, including iron limitation.
In chapter 2, we demonstrate that, contrary to other staphylococci, S. lugdunensis
does not produce a siderophore – small (<1 kDa) iron-chelating molecules that strip iron
from host glycoproteins, including transferrin, and deliver it to microorganisms. As such,
serum is growth-inhibitory to S. lugdunensis, unless it is supplemented with an iron source.
We have identified and characterized several iron-compound transport processes through
inactivation of genes required for acquisition of each respective compound. S. lugdunensis
transports the staphylococcal carboxylate siderophores staphyloferrin A and staphyloferrin B
through Hts and Sir, respectively, and is able to directly appropriate siderophores produced
by S. aureus when in coculture, to support its growth. Heme and hemoglobin-iron is acquired
via Isd.

In chapter 3, we demonstrate that hemolysis enhances growth in blood, in an Isddependent manner. An iron-regulated ATPase, FhuC, is required for import of several
carboxylate and hydroxamate siderophores, whereas Sst1 transports catecholamine stress
hormone-iron (ie. adrenaline, noradrenaline, dopamine). fhuC and sst1 mutants are impaired
for growth in absence of hydroxamates and catecholamines, indicating additional substrates
acquired by these are vital to S. lugdunensis. Using a novel systemic model of S. lugdunensis
infection, we show that a isd fhuC sst mutant is significantly impaired in its ability to
colonize internal murine organs, and cause sickness. We have detailed several ironacquisition systems in S. lugdunensis and are first to show specific transporters are important
for pathogenesis in the host.

Keywords
Staphylococcus lugdunensis, iron, heme, hemoglobin, siderophores, staphyloferrin A,
staphyloferrin B, hydroxamates, catecholamine stress hormones, hemolysis
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Chapter 1
Literature Review

2

1.1 Iron
1.1.1

Iron chemistry

Iron is an essential nutrient for nearly all forms of life. It is crucial for vital cellular
processes including DNA replication, amino acid synthesis, tricarboxylic acid cycle
(TCA) activity and respiration. The functional versatility of iron is owed to its ability to
readily interconvert between valence states, imparting single electron transfer chemistry
to reactions that include almost the entire range of biologically significant redox
potentials (1). Although able to achieve oxidation states between -2 and +6, iron is
predominantly found in Fe2+ (ferrous) and Fe3+ (ferric) redox states. Ferric iron
predominates in aerobic, oxidizing environments and forms insoluble hydroxides, with
the predominant species at neutral pH being Fe(OH)+2 (2). This renders the solubility of
iron in solution to be 10-8 to 10-9 M, well below the threshold to support microbial growth
(~10-6 M) (3). Further restricting bioavailable iron is important to suppress infectious
pathogen growth, and to keep it from undergoing reactions forming toxic products.
Ferrous iron is able to catalyze the formation of free radicals, which are able to oxidize
and damage cells (4).

1.1.2

Iron toxicity

Despite its low solubility in physiological conditions, the ability of residual free iron to
readily interconvert between 2+ and 3+ redox states makes it a catalyst for production of
harmful reactive species. Toxic reactive oxygen species (ROS) are produced through the
Haber-Weiss reaction and Fenton chemistry (5, 6). Fe2+ reacts with hydrogen peroxide to
form hydroxyl radicals (Equation 1), whereas Fe3+ reacts with hydrogen peroxide
(Equation 2) or superoxide radical (Equation 3) to regenerate Fe2+, shown in the three

3

equations below. Altogether, free iron is able to generate toxic species, of which the
hydroxyl radical is extremely cytotoxic and capable to damage lipids, proteins and
nucleic acids (7–10). Cellular life requires iron, and consequently must mitigate its
toxicity. As such, biological systems tightly control iron mobility and storage with
elaborate sequestration and transport methods.
Fe2+ + H2O2

è

Fe3+ + OH− + OH

(Equation 1)

Fe3+ + H2O2

è

Fe2+ + H+ + OOH

(Equation 2)

Fe3+ + O2−

è

Fe2+ + O2

(Equation 3)

1.2 Iron processing in mammals
1.2.1

Iron absorption

Human iron metabolism is necessary to maintain homeostasis and important for
promoting good health. Iron storage and trafficking within the human body has been
extensively reviewed elsewhere (11–13). Briefly, iron from dietary sources is absorbed
chiefly in the duodenum, with the absorbed amount dependent on sufficiency of stored
iron in the body. The low pH of the intestinal lumen and ferric reductases in the apical
brush border of duodenal enterocytes facilitate reduction of ferric iron to the more soluble
ferrous form. Ferrous iron is transported into enterocytes through the divalent metal ion
transporter DMT1 (Nramp2) (14). The internalized iron may be used for cellular
processes, put into storage, or released into plasma via the basolateral membrane
transporter ferroportin (15, 16). Macrophages recycle iron from senescent or dead cells,
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including erythrocytes, and also elaborate ferroportin on their membrane. Nearly all iron
in plasma is bound to the carrier protein transferrin, further described below.
A typical adult contains approximately 4-5 g of total iron in their body. Iron
metabolism is regulated systemically by the peptide hormone hepcidin. A surplus of iron
in the body stimulates hepcidin release from the liver. Hepcidin binds ferroportin on
enterocytes and macrophages and triggers internalization and degradation, thereby
decreasing iron export into circulation (17). Further absorbed dietary iron may be stored
within intracellular ferritin protein, and excess iron may be shed from the body via
enterocyte sloughing and feces production.

1.2.2

Iron storage

Ferritin is a primary means of iron storage for animals, microorganisms and plants alike.
The mammalian ferritin is 450 kDa and made up of 24 heavy and light chains that
together facilitate iron uptake into the hollow core of the large spherical protein (18, 19).
Each ferritin structure may hold up to 4,500 iron atoms in the form of hydrous ferric
oxides (19). Ferritin is abundant in liver hepatocytes, which essentially function as an
iron storage and transport hub for the body (20). Additionally, ferritin release into plasma
may aid in iron delivery to other tissues, including the brain and erythroid precursors
(21–23). Furthermore, elevated serum ferritin is a nonspecific indication of infection or
cancer, and can robustly predict cirrhosis development from hemochromatosis (24–26).
Elevated serum ferritin is atypical of physiologically normal conditions and generally
indicates an iron overload that may be associated with various disease states.
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1.2.3

Iron for cellular processes: intracellular hemoproteins

The catalytic versatility of iron renders its usage in a number of cellular proteins
including those that incorporate iron-sulfur clusters as redox cofactors, and in heme
prosthetic groups within hemoproteins. Iron-sulfur proteins are predominantly involved
in oxidoreductase, hydrogenase, dehydrogenase and hydratase reactions and are best
known to offer redox capability for mitochondrial electron transport (27–30). The
majority of bodily iron is complexed in heme within hemoproteins such as catalase,
peroxidase, cytochromes, and foremost hemoglobin. Hemoglobin accounts for two-thirds
of total iron within the body, the majority of which circulates within erythrocytes (31).
The heme prosthetic group consists of a planar heterocyclic ring (porphyrin) able to
coordinate a central iron atom with four nitrogen bonds. The central iron is able to form
two additional coordinate bonds somewhat perpendicular to porphyrin and may interact
with axial ligands including histidine, cysteine, tyrosine and methionine residues of
binding proteins. Peroxidases and gas-carrying proteins such as hemoglobin contain
heme B (protoporphyrin IX-iron), the most abundant type of heme. Other types of heme
have various different constituents linked to the central porphyrin ring to differentiate
compound chemistry for different purposes, including aspects of aerobic respiration and
pathogen defense (32–34).
Each erythrocyte may contain more than 2.8 x 108 molecules of hemoglobin, and
constitute the most abundant source of hemoglobin in the body (12). Hemoglobin is a
globular heterotetramer in which each subunit coordinates a heme group with an
imidazole nitrogen from a histidine. The sixth coordinate position of iron is left to bind
O2 and facilitate delivery from lungs to tissue. The average erythrocyte life span under
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normal conditions is ~120 days, although these cells are more prone to oxidative damage
due to their large amount of heme iron and great exposure to oxygen (35, 36).
Erythrocyte lysis and hemoglobin damage lead to free heme and hemoglobin in serum.
Extracellular hemoglobin tetramer is scavenged by the glycoprotein haptoglobin, which
binds specifically and irreversibly (37). The haptoglobin-hemoglobin complex binds a
receptor on the surface of macrophages for internalization and degradation (38). Iron is
released from the porphyrin ring and recycled into transferrin or hemosiderin, a complex
of ferritin and denatured ferritin (39, 40). Free heme in serum is primarily absorbed by
the lipid core of the highly-abundant, fat-transport protein albumin (high or low density
lipoprotein) (41). It is transferred to the glycoprotein hemopexin, which bears a very
strong affinity for heme. The hemopexin-heme complex binds receptors on hepatocytes
or macrophages for internalization and recycling in a similar manner to haptoglobinhemoglobin employing lysosomal degradation (42, 43).

1.2.4

Iron transport: extracellular iron

Transferrins are glycoproteins of approximately 80 kDa that circulate in biological fluids,
including serum, to facilitate iron transport between tissues (44). Although comprising
less than 0.1% of total body iron (<5 mg), this reservoir constitutes an important means to
limit free iron and control iron homeostasis (45, 46). A healthy adult has a serum
transferrin concentration of ~25-30 µM (47, 48). Each transferrin glycoprotein has two
high affinity Fe3+ binding sites, with stability constants of 4.7 x 1020 M-1 and 2.4 x 1019
M-1 at pH 7.4 (49). Iron-binding is random and noncooperative between the two domains
and serum transferrin is typically ~30% saturated, while 20-50% saturation indicates a
healthy state (50, 51). Synthesized by the liver, transferrin binds ferroportin-released
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ferric iron (from intestinal enterocytes or other sources) and distributes bound iron to
cells bearing transferrin receptor, which is ubiquitously expressed. Cells that require iron
upregulate transferrin receptor expression. Holo-transferrin binds cell-surface exposed
transferrin receptor and initiates receptor-mediated endocytosis for internalization and
maturation into an endosome. A decrease in endosomal pH (below 5.5) triggers iron
release from transferrin, which bears little affinity for ferrous iron. The released iron is
mobilized for cellular processes or storage, whereas the endosome returns to the cell
surface. The extracellular neutral pH allows apo-transferrin dissociation from transferrin
receptor, such that apo-transferrin is released back into circulation to complete the
transferrin cycle (52, 53). Additionally, the membrane protein HFE (human
hemochromatosis factor) interacts with transferrin and transferrin receptor to detect
saturation of transferrin and regulate hepcidin production to modulate iron absorption
(54, 55). Transferrin receptor and ferritin expression is also regulated
posttranscriptionally by iron-regulatory RNA-binding proteins (IRPs), which bind to
iron-responsive elements (IREs) in mRNA to alter stability and translation efficiency
(56).
Lactoferrin is a glycoprotein closely related to transferrin in sequence and
structure, although it functions predominantly for scavenging iron rather than for
transport (57). Found primarily in bodily secretions, lactoferrin releases bound iron at
approximately pH 3 (compared to pH 5.5 for transferrin), and may act as a potent
microbicidal agent by limiting available iron under various conditions (58). For this
purpose, polymorphonuclear leukocytes release lactoferrin during degranulation upon
phagocytosis (59). Released lactoferrin sequesters iron to prevent bacterial adherence and
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promote bacteriostasis (60, 61). Lactoferrin-iron may also be used to catalyze free radical
production via granule-phagosome fusion (62). Although having no significant role for
iron transport, lactoferrin performs an important function for defense against pathogen
infection by binding iron in bodily secretions and sites of infection.

1.2.5

Nutritional immunity: iron withholding

The human body takes advantage of the essentiality and toxicity of transition metals to
protect itself against foreign invaders by restricting available nutrients, such as iron, to
limit infection. Conversely, disease states associated with iron overload such as
hemochromatosis, thalassemia, and hemoglobinopathies are associated with increased
available serum iron and susceptibility to infection (63, 64). The inflammatory response
results in further iron withholding in serum, including suppression of iron absorption
from the diet and increased macrophage iron retention, creating an anemic environment
(hyposideremia) (65). Hepcidin is upregulated by interleukin-1α, interleukin-1β,
interleukin-6, and sustained H2O2 (66, 67). Increased hepcidin production by the liver and
spleen during inflammation is responsible for triggering ferroportin degradation and
reduced iron absorption (68).
Another facet of iron withholding is the rapid expulsion of iron-sequestering
proteins. Hepatocytes secrete ferritin in response to interleukin-1β, whereas interleukin-6
stimulates haptoglobin and hemopexin secretion (69–71). Lactoferrin is produced by
neutrophils at sites of infection to restrict iron availability (72). Neutrophil secretion of
calprotectin (S100A8/A9) is induced in response to infection in order to restrict
manganese, zinc and iron availability (73, 74). Calprotectin is a calcium-binding
S100A8/A9 heterodimer or heterotetramer that exhibits broad spectrum growth inhibition
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of infectious microbes through sequestration of the aforementioned nutrients (75). Each
subunit binds two calcium ions, which help to facilitate greater binding affinity for two
transition metal ions at the heterodimer interface (76, 77). In addition to calprotectin,
extracellular S100A7 and S100A12 are present in high concentration in inflamed tissue,
where they act as damage-associated molecular patterns and elicit immunomodulatory
activity (78, 79). Serum transferrin concentration, on the contrary, is maintained during
inflammation, however saturation remains low as this iron source is continued to be
depleted by erythropoiesis (80–82). Iron sequestration as a method of nutritional
immunity is a forefront function of the innate immune system to help combat infection.

1.3 Host-iron acquisition strategies of pathogenic
eukaryotes
1.3.1

Iron acquisition by pathogenic fungi

Iron is an essential nutrient for nearly all species that infect humans, and pathogens must
elaborate means to overcome host iron withholding to successfully colonize and cause
disease. The essentiality of iron necessitates a diversity of mechanisms to acquire iron
from a variety of host sources, to better ensure pathogen survival. Pathogenic fungi, like
many other microorganisms, upregulate iron acquisition machinery upon sensing a low
iron environment such as the mammalian host. Thus, lack of iron serves as a signal for
transition from a commensal to a more invasive lifestyle. Aft1p and Aft2p transcription
factors regulate iron acquisition systems by binding iron-responsive elements in target
gene promoter regions to activate gene expression, and control the iron regulon in yeast
(83, 84). Three predominant iron acquisition strategies have been described: iron
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reduction and transport, ferric-siderophore uptake and heme acquisition (85). The various
strategies are not exclusive and may occur simultaneously.
Opportunistic fungal pathogens use coupled iron-reduction and transport for iron
acquisition from host chelating molecules, including transferrin and lactoferrin. Cell
surface, non-specific metalloreductases Fre1 and Fre2 reduce iron at the cell surface (86,
87). Ferrous iron is subsequently oxidized by Fet3 and translocated across the membrane
by the Ftr1 permease, with oxygen, copper, and heme as cofactors, serving as a highaffinity iron acquisition pathway (88–90). Reductive iron uptake is required for full
virulence of fungal species, such as Candida albicans and Cryptococcus neoformans, in
animals (91, 92).
High affinity non-reductive iron uptake is mediated by siderophores - low
molecular weight (typically <1 kDa), high-affinity iron binding compounds that many
microbes produce and are able to strip iron from host glycoproteins (such as transferrin
and lactoferrin) (4, 93, 94). Most bacteria and fungi synthesize and secrete siderophores,
which bind extracellular ferric iron and deliver it to microbes expressing a receptor for
that specific siderophore. Fungi typically produce siderophores bearing hydroxamate
moieties to coordinate iron, although many fungal species transport other types of
siderophores from heterologous species as well (ie. catechol siderophores produced
predominantly by bacteria) (85). This xenosiderophore ‘sharing’ is a cooperative
behaviour in microbial communities where individual metabolic cost is outweighed by
group benefit. Additionally, siderophore-iron may be reduced at the cell surface (as
explained above) when siderophores are relatively abundant (95). At lower siderophore
concentrations, siderophore-specific membrane transporters are required for uptake of
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ferric siderophores from the external environment (95, 96). Fungal siderophore transport
and specificity of receptors has been comprehensively reviewed elsewhere (88, 97).
Siderophores are discussed in further detail in subsequent sections. Reliance on reductive
iron uptake versus siderophore acquisition differs between species and one or both may
be important to certain species of fungi for pathogenesis. Although Aspergillus fumigatus
is capable of iron reduction at the cell surface, this activity is insufficient to fully
compensate for the absence of siderophore biosynthesis and acquisition, which is
furthermore essential for virulence in animals (98, 99). Moreover, intracellular
siderophores help maintain iron storage and distribution, as well as promoting
germination and resistance to oxidative stress (100).
The heme-dependent growth of several fungal species has been demonstrated
(101–104). The most characterized of these is C. albicans iron acquisition from heme and
hemoglobin. C. albicans binds erythrocytes using complement-receptor like molecules,
and secretes a hemolytic mannoprotein to exhibit red cell lysis (105–107). Surfaceexposed, cell wall-anchored CFEM domain proteins Rbt5 and Rbt51 bind hemoglobin
and extract heme at the cell surface (108). CFEM domains are unique to fungi, contain
eight cysteine residues of conserved spacing, and are important for pathogenicity (109,
110). Rbt5 and cell-wall associated Pga7 (not surface-exposed) exchange heme as a relay
to the plasma membrane upon which heme is endocytosed in a Rbt5-dependant manner
(111, 112). A type I myosin and the ESCRT system are required for endocytosis, whereas
a vacuolar ATPase and a heme oxygenase are further required for heme-iron utilization
(112, 113). The heme oxygenase Hmx1 is required for virulence in the mammalian host
(114). Other pathogenic fungal species may use similar means for heme-iron
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procurement. In C. neoformans, the ESCRT pathway is also important for heme-iron
acquisition, and extracellular, heme-binding Cig1 is a potential hemophore that
contributes to virulence (102, 115).

1.3.2

Iron acquisition by human parasites

Human parasites exhibit great diversity in terms of lifecycles and associated niches and
as such elicit diverse strategies of obtaining host nutrients such as iron. Trypanosoma
brucei, Leishmania spp., Plasmodium spp., and hookworms cause substantial disease
burden in humans and will be the focus here.
T. brucei is a flagellated protist that uses an insect vector (tsetse fly) to transmit
between mammalian hosts and is known to cause sleeping sickness in humans.
Trypanosomes reside in the mammalian bloodstream, lymphatic system and interstitial
spaces and may progress to the central nervous system in later stages of infection (116).
They exploit host transferrin via receptor-mediated endocytosis at the flagellar pocket
(invagination of the plasma membrane at the flagellum) (117). Structurally distinct from
human transferrin receptor, the trypanosome counterpart is regulated by iron availability
and encoded by ESAG6 and ESAG7 to form a heterodimer (118, 119). Upon
endocytosis, acidification releases iron from the transferrin-receptor complex and is
transported to the cytosol by a mucolipin-like protein (120, 121). Proteolytic cleavage of
the transferrin receptor precedes endosomal cycling back to the cell surface (120). T.
brucei may also bind lactoferrin in a similar manner to macrophages via glyceraldehyde3-phosphate dehydrogenase (GAPDH), although this remains to be fully elucidated (122,
123). Trypanosomes are heme auxotrophs and acquire heme-iron mainly through a
haptoglobin-hemoglobin receptor (HpHbR) exclusively expressed when in a mammalian
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host environment (124, 125). The surface anchored glycoprotein localizes to the flagellar
pocket region and undergoes endocytosis prior to heme-iron extraction (125). The freeheme transporter Hrg is exclusively expressed during insect vector-stage growth (125,
126). Trypanosome-induced macrophage hyper-activation leads to increased
erythrophagocytosis and iron retention, leading to progressive anemia during chronic
infection (127).
Leishmania protozoan parasites cause a spectrum of clinical manifestations
ranging from cutaneous lesions to visceral infections, termed leishmaniasis (128). Motile,
extracellular promastigotes multiply in the sand fly gut, whereas upon mammalian
inoculation, infective parasites reside as non-motile amastigotes in the phagolysosomal
system of macrophages (129). The Leishmania-carrying phagosome fuses with other
vacuoles and endosomal compartments which carry nutrients, such as transferrin (as
transferrin-receptor complex) as a source of iron for the parasite (130–132). Furthermore,
the phagosomal acidity may release iron from transferrin, or transferrin may be degraded
by secreted cysteine proteases (or released by lysed parasites) (131, 133). Leishmania
plasma membrane-associated ferric reductase LFR1 reduces Fe3+ to Fe2+ using NADPH,
FAD and heme as cofactors (134, 135). Fe2+ is transported to the cytosol by LIT1,
serving as a non-specific, reductive iron transport mechanism (136). LFR1 and LIT1 are
iron-regulated and detected on intracellular amastigotes and iron-starved promastigotes
(135, 137). Leishmania may also be able to endocytose and degrade transferrin in
cysteine protease-rich compartments, although this may be a non-specific interaction as
lactoferrin and albumin also bind the receptor (134, 138). Only the last three enzymes of
the heme biosynthetic pathway are present in Leishmania trypanosomatid parasites, thus
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requiring external heme or protoporphyrin IX (PPIX) for growth (139). The Leishmania
hemoglobin receptor localizes to the flagellar pocket and upon hemoglobin binding is
endocytosed (140, 141). Endosomal maturation is mediated by Rab 5 and Rab 7, and
lysosomal hemoglobin is degraded to release heme, which is translocated to the cytosol
by the ATP-binding cassette protein LABCG5 (142–144). Leishmania heme utilization
correlates with severity of patient anemia (145). Transmembrane LHR1 transports
external or lysosomal heme directly into the cytosol and is important for causing
pathogenesis in mammals (146, 147). Furthermore, LHR1 is proposed to be essential for
promastigote viability, and orthologs are present in several Trypanosoma genomes as
well (146, 148, 149).
At least five Plasmodium species are able to cause malaria in humans, with P.
falciparum being the most deadly. Using a mosquito vector of transmission, the parasitic
protist enters the human bloodstream and travels to the liver to infect hepatocytes.
Infected hepatocytes eventually lyse to expel non-motile merozoites into the bloodstream
to infect (and further re-infect) red blood cells (150). The intraerythrocytic stage of
infection offers a gold mine of heme for the pathogen, however it actually uses
hemoglobin primarily as a source of amino acids rather than iron, albeit still annihilating
the host iron pool. Furthermore, iron deficiency is protective against malaria and iron
supplementation increases risk of malaria (151). Initially, the parasite folds into itself in
an actin-independent process to invacuate a large ‘gulp’ of host red cell cytoplasm as a
food vacuole (152). Later on, host hemoglobin is endocytosed with other erythrocyte
components into cytostomes, and further targeted for acidification and proteolytic
degradation in an actin-dependent process regulated by Rab 5 (152–154). Together, P.
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falciparum uses various means of internalizing large amounts of host hemoglobin, which
are directed to digestive vacuoles for degradation as a source of amino acids (155).
Hemoglobin is digested sequentially by aspartic proteases, cysteine proteases,
metalloproteases and aminopeptidases (156, 157). The large amount of toxic free heme is
polymerized into pigmented crystals termed hemozoin (158, 159). Heme groups dimerize
via iron-carboxylate bonds, and dimers are bonded via proprionate hydrogen bonding
(160, 161). Protease and hemozoin-formation inhibitors block parasite development and
detoxifying capabilities, hinder viability and form potent antimalarial drugs (159, 162–
164). This is exemplified by the potency of quinolone drugs for P. falciparum infection
as they inhibit hemozoin synthesis and the parasites ability to detoxify heme, as it
produces reactive oxygen species. Lysed protists release hemozoin to be ingested by
phagocytes and accumulate in the reticuloendothelial system, which leads to a darkening
of the liver and spleen after chronic or repeated infection (165, 166).
Human hookworm infection results in intestinal blood loss due to hematophagous
feeding and causes substantial iron deficiency anemia in the developing world (167).
Intensity of hookworm infection directly correlates to intestinal blood loss and host
anemia. Hosts with lower iron stores, such as children and pregnant women, are more
vulnerable to hookworm-induced anemia (168). Necator and Ancylostoma species cause
the majority of hookworm disease in humans (169). The nematode helminths infect the
mammalian host at the larval stage by oral ingestion or skin penetration (170). Larvae in
circulation travel to the heart and lungs, penetrate the alveolar membrane and enter the
trachea for migration to the gastrointestinal tract (171). The larvae mature in the
gastrointestinal tract and attach to the duodenal mucosa, where they can reside for years
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(172). Host capillaries are lacerated and secreted anticoagulant peptides help facilitate
ingestion of blood (173). Ingested red cells are lysed in the hookworm gut by a poreforming, membrane-bound hemolysin (174). Hemoglobin digestion is similar to that of P.
falciparum, using aspartic, cystic and metalloproteases, albeit expressed in and released
from the intestinal brush border of the helminth (175, 176). Glutathione-S-transferases
are thought to play a role in heme detoxification as several of these bind heme with high
affinity (177–180). Additionally, vaccination using recombinant hookworm glutathioneS-transferases elicited better protection against infection in hamsters and dogs (177, 181).

1.4 Host-iron acquisition strategies of pathogenic
prokaryotes
1.4.1

Active transport across membranes

The host confines iron within proteins to mitigate the generation of damaging reactive
species, and to help prevent infectious disease (nutritional immunity). As such the
concentration of free iron in body fluids can be restricted up to 10-24 M, far below that
required to support microbial growth (10-6 M) (3, 182). Invasive pathogens respond to
this nutritional immunity by elaborating specialized, high-affinity iron transport
mechanisms able to circumvent host immune effectors.
Bacterial iron acquisition strategies generally rely on free (un-liganded) ferrous
iron, heme, and siderophore transport (Figure 1-1). All of these mechanisms rely on
active transport across bacterial membranes, involving ATP-binding cassette (ABC)
transporters. In Gram-negative bacteria, the presence of an outer membrane necessitates
specific receptors for substrate recognition for larger compounds (>600 Da) including
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Figure 1-1: Nutritional immunity and strategies of pathogens to overcome host iron
limitation. Representative depiction of various strategies bacterial pathogens employ to
attain host-iron. At the mucosa, lactoferrin (Lf) binds iron yet some bacteria are able to
obtain this iron through secretion of siderophores (i – iii), binding Lf (iv), or secreting
reductases (v – viii) to reduce iron to Fe(II). Bacteria may lyse cells through secreted
hemolysins and obtain released heme/hemoglobin (Hm/Hb), as well as host-scavenged
hemopexin-heme (Hx-Hm) and haptoglobin-hemoglobin (Hp-Hb) iron (1 – 12).
Macrophages remove iron from phagosomes via natural resistance macrophage protein 1
(NRAMP1) and ferroportin. Membrane-bound ferroportin is degraded when bound by the
iron homeostasis hormone hepcidin. Ceruloplasmin (Cp) oxidizes secreted Fe(II), and
Fe(III) is bound by transferrin (Tf) in circulation (a, b). Transferrin-iron may be procured
via direct transferrin-binding (c), by secreted siderophores (Sid) (d – f), or host-produced
compounds such as 2,5-DHBA (g). Siderocalin (NGAL) produced by neutrophils
sequesters several siderophores (I – III), although some ‘stealth’ siderophores (Sid
stealth) are unrecognized by NGAL (IV – VI). Lf, lactoferrin; Hm, heme; Hb,
hemoglobin; Hx-Hm, hemopexin-heme; Hp-Hb, haptoglobin-hemoglobin; Cp,
ceruloplasmin; Tf, transferrin; Sid, siderophore; NGAL, siderocalin; Sid (stealth), stealth
siderophore. Figure procured from (183).
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transferrin, lactoferrin, hemoglobin, and siderophores (184). The outer membrane
receptors are β-barrel pores made of antiparallel β-sheets, with an N-terminal globular
‘plug’ that seals the pore until substrate-binding and energy transfer cause conformational
changes to allow iron, heme or siderophore passage (185). The energy for this process is
derived from the proton motive force across the inner membrane, channeled through the
TonB, ExbB and ExbD complex (186, 187). The substrate is bound by a freely soluble,
bilobal, periplasmic binding protein (PBP) with specificity for that ligand (188). The
substrate-PBP complex is recognized by an inner membrane permease which translocates
the substrate across the lipid bilayer using energy generated by an associated ATPase
(185). The inner membrane permease is typically a homo or heterodimer spanning the
membrane whereas the associated ATPase is a cytoplasmic homodimer (189, 190).
Gram-negative bacterial active transport has been characterized and reviewed in detail
elsewhere (184–190).
Gram-positive bacteria employ a similar means of active transport utilizing an
integral membrane ABC transporter, although the PBP-functionally equivalent, high
affinity receptor is linked to the cytoplasmic membrane by a lipidation motif. The Grampositive cell wall is composed of a meshwork of peptidoglycan, polysaccharides, teichoic
acid, and associated proteins of varying glycosylation. Although siderophores are able to
pass through this meshwork, heme must be extracted from host proteins prior to cell wall
transversion (191).

1.4.2

Free ferrous iron transport

Ferric iron predominates under oxidizing conditions and may become bioavailable via
siderophores or reduction to ferrous iron. Ferrous iron predominates in anoxic, low pH
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environments and can become an important iron source for bacterial pathogens in certain
situations. The ferrous iron transport (Feo) system is present in many bacteria, although
most extensively characterized in Enterobacteriaceae (192, 193). FeoB is a cytoplasmic
membrane-spanning permease with a cytosolic GTPase domain driving active transport
(194). Cytosolic FeoA interacts with the G-protein domain of FeoB and is required for
FeoB-iron transport (195). FeoC is only present in γ-proteobacteria Feo systems and
although initially thought to act as a transcription factor, more recent evidence indicates
FeoC interaction with the FeoB N-terminal region for protection from FtsH-mediated
proteolysis (196, 197). The putative FeoC-associated iron-sulfur (Fe-S) cluster may
function as a redox/iron sensor as Fe-S cluster reduction renders it less susceptible to
Lon-mediated proteolysis. In oxidizing environments, the FeoC Fe-S cluster is thought to
become oxidized and degraded, facilitating FeoB-FeoC release and FeoB proteolysis as a
means of post-translational regulation (198). Feo homologs exist in the genomes of many
Gram-positive and Gram-negative bacteria.
ABC-type divalent metal transport has been described for many Gram-positive
and Gram-negative species. SitABC (homologous transporters also termed MntABC or
MtsABC) homologs across species vary in transport of ferrous iron, manganese or both.
Staphylococcus epidermidis Sit is regulated by both iron and manganese availability
through SirR, which represses transcription in presence of Mn2+ or Fe2+ (199–201). S.
epidermidis Sit is highly upregulated in iron limited conditions such as those in vivo
(202–204). The S. aureus homolog (MntABC) is a dedicated manganese transporter,
repressed by MntR in the presence of Mn2+ (205). The streptococcal homolog (MtsABC)
is regulated by Mn2+ and Fe2+ and can bind several divalent metals, with a preference for
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ferrous iron over copper, manganese and zinc (206–208). Salmonella enterica SitABCD
has high affinity for manganese over iron, although is regulated by both manganese and
iron (209, 210). Sit systems in Shigella species and pathogenic E. coli are orthologous to
YfeABCD in Yersinia and share overlapping functions with Feo and the manganese
transporter MntH, although there are some variations in regulation between the metal
acquisition systems which may play a role in response to oxidative stress (211–215).
Although best characterized in eukaryotes, some bacteria may also possess ferric
reductase activity as a mechanism of making iron bioavailable for acquisition.
Extracellular and membrane-associated ferric reductase activity has been described for a
variety of bacteria, and biochemical characterization of molecular determinants for this
iron uptake strategy has been progressing (216–220). E. coli EfeUOB (YcdNOB) is
upregulated in low iron and low pH conditions, and is involved in ferrous iron acquisition
(221, 222). EfeU is homologous to the Ftr1 permease in yeast (221). EfeO is periplasmic
with two potential metal binding sites and an N-terminal cupredoxin domain, which
implies it functionally analogous to the Fet3 oxidase (223). EfeB is a periplasmic
homodimer secreted by the twin-arginine translocation (Tat) system as a folded protein
(224, 225). Bacillus subtilis also encodes efeUOB whereas orthologous genes are termed
fepCAB in Listeria monocytogenes and S. aureus (226–228). Although EfeB and FepB
have been implicated in heme deferrochelatase activity, removing iron from heme while
keeping the tetrapyrrol ring intact, there is some contention to this proposed activity as
PPIX is toxic and lacks a degradative pathway (224, 229, 230). Overexpression of YfeX
(cytoplasmic EfeB homolog) results in intracellular porphyrin accumulation, likely from
oxidation of endogenously synthesized porphyrinogen, and it may be that homologous
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EfeB/FepB oxidize porphyrinogens to porphyrins as well (230). L. monocytogenese FepB
exhibits ferric reductase activity, whereas B. subtilis EfeB oxidizes ferrous iron for
uptake of ferric iron by EfeUO, indicating there may be functional variation with varied
environmental conditions (226, 227). Natural substrates for EfeB/FepB-mediated
oxidation or reduction have not been established and could entail iron-binding
compounds in the host such as transferrin and siderophores (191). Additionally, the
secretion of a fully folded EfeB/FepB with endogenous heme may be an oxidative stress
response to counter damage from reactive oxygen/nitrogen species, such as would be
encountered during an immune response (respiratory burst) (225).

1.4.3

Direct iron acquisition from host proteins

Several pathogenic bacteria express surface receptors to bind host iron-withholding
glycoproteins and extract iron from them. Neisseria spp. preferentially acquire iron from
host transferrin through the TbpAB outer membrane receptor, which is essential for
virulence in human infection (Figure 1-2) (231, 232). Lipoprotein TbpB binds transferrin
and facilitates interaction with transmembrane TbpA to extract iron by conformationally
manipulating transferrin in a TonB-dependent manner (233, 234). LbpAB also utilize
TonB/ExbB/ExbD and function in a similar manner to transport lactoferrin-iron (235–
237). Periplasmic ferric iron is bound by FbpA and further shuttled through FbpBC into
the cytoplasm (185, 238, 239). Homologous receptors that bind and extract iron directly
from transferrin and lactoferrin also exist in Pasteurellaceae and Moraxellaceae (235,
240–242).
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Figure 1-2: Schematic of iron-acquisition mechanisms in Gram-negative and Grampositive bacteria. Depictions of cell envelope proteins mediating uptake of siderophores
(Sid, unspecified transporter), heme (Hm, HasAR), transferrin (Tf, TbpAB) and ferrous
iron (FeII, FeoB) In Gram-negative bacteria. Siderophore (unspecified transporter) and
heme acquisition from hemoglobin (Hb) and hemoglobin-haptoglobin (Hb-Hp) via Isd
proteins is depicted for Gram-positive bacteria. Further detail on transporters is within the
main text. OM, outer membrane; PG, peptidoglycan; CM, cytoplasmic membrane; Sid,
siderophore; Hm, heme; HO, heme oxygenase; Tf, transferrin; Hb, hemoglobin; Hb-Hp,
hemoglobin-haptoglobin. Figure procured from (183).
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1.4.4

Indirect iron acquisition from host proteins: siderophores

Siderophores are low molecular weight (~500 – 1500 Da), high affinity Fe3+ chelators
produced by a large number of bacteria, fungi and plants to facilitate iron delivery in
response to iron limitation (93). There is stunning diversity between siderophore
structures and they may be classified as to their iron-coordinating moieties (hydroxamate,
catecholate and hydroxycarboxylate), although certain siderophores may encompass
more than one type of moiety to coordinate iron as a ‘mixed type’ siderophore. The small
ferric chelators scavenge ferric iron and compete for it with other iron chelates.
Siderophore-iron association constants can exceed 10-52 M, and as such they are able to
remove iron from host glycoproteins including transferrin and lactoferrin (association
constants of ~10-20 M) (49, 243, 244). The ferric-siderophore complex is recognized at
the surface of cells expressing a cognate receptor for that specific substrate, engendering
the organism with an iron-sourcing advantage (Figure 1-2).

1.4.5

Siderophore biosynthesis

Siderophore production occurs within the cell and may be through nonribosomal peptide
synthetase(NRPS)-dependent or NRPS-independent synthesis. NRPS synthesis involves
successive incorporation of non-proteinogenic amino acids and derivatives into an
elongated chain, without the use of an RNA template (245). In addition to assembly of
several common Gram-negative enteric siderophores including enterobactin, vibriobactin
and yersiniabactin, NRPS mechanisms are also used to produce antimicrobial peptides
such as penicillin and vancomycin (96, 246, 247). Independent of ribosomal peptide
assembly, a multimodular NRP synthetase activates or modifies covalently linked
reaction intermediates to control the iterative production of the compound via its catalytic
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domains (248). Enterobactin synthesis is arguably the most extensively-characterized
NRPS-dependent siderophore biosynthetic pathway. entA-F genes in E. coli encode
subunits of the multienzyme complex that converts chorismate (intermediate in aromatic
amino acid biosynthesis) to the catechol 2,3-dihydroxybenzoic acid (2,3-DHB). Three
molecules of 2,3-DHB are linked to 3 molecules of L-serine via three amide and three
ester bonds to produce the catecholamine siderophore enterobactin (249–252). The
catecholamine siderophore petrobactin is a rare example of a product assembled by both
NRPS-dependent and independent synthetases (253).
NRPS-independent synthesis, on the other hand, is performed by individual
cytoplasmic synthetases that catalyze amide or ester bond formation between
dicarboxylic acids (commonly citrate, succinate or α-ketoglutarate), diamines, alcohols or
amino alcohols. The alternating siderophore subunits are linked by condensation
reactions by the synthetases, which are not homologous to NRPS pathway counterparts
(254). Aerobactin is produced by several pathogenic Gram-negative bacteria (including
E. coli), contains hydroxamate and hydroxycarboxylate iron-coordinating moieties, and is
the archetypal pathway for NRPS-independent siderophore biosynthesis. A four-gene
cluster encodes IucA-D, which modify and condense two molecules of L-lysine with a
citric acid linker in a presumably ATP-dependent process (255). A model has been
proposed, based on phylogenetic analyses, to classify NRPS-independent synthetases
based on substrate specificity (256). Type A enzymes such as IucA are specific for citrate
and condense a prochiral carboxyl group of citrate with an alcohol or amine functional
group of another substrate. Type B enzymes have specificity for α-ketoglutarate and
substitute the C5 carboxyl group for a citrate carboxyl group. Type C enzymes, including
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IucC, are specific for citrate or succinate derivatives and condense the
monoamide/monoester with an amine or alcohol. The multitude and diversity of
siderophore structures infers that these ‘guidelines,’ formed on the basis on sequence
analysis, are simply a few of the more characterized biosynthesis mechanisms, and many
exceptions exist. Microorganisms may have great variations in the ways they produce a
certain NRPS-independent synthesized siderophore. Modifications to precursor
molecules, such as oxidation, isomerization, or decarboxylation are catalyzed by enzymes
encoded by genes adjacent to, or within siderophore biosynthetic loci. Many other
siderophores have been suggested to be produced by NRPS-independent methods
including vibrioferrin, rhizobactin, alcaligin, and desferrioxamine (257–260).

1.4.6

Siderophore structure

Although there is great diversity between siderophore structures, there are common
features that make them very good iron acquisition mechanisms. They are small,
electronegative compounds that coordinate Fe3+ with six donor coordination sites, at best.
If less than six iron-coordinating donor atoms are present, surrogate electronegative
bonds with solution molecules may facilitate further coordination. Higher order
siderophore to iron stoichiometry than the typical 1:1 is possible when fewer coordination
moieties exist within the siderophore. Examples include 2(iron):3 rhodoturolic acid, 1:3
cepabactin, and 1:1 or 2 pyochelin complexes (261–263). Mixed complexes of cepabactin
and pyochelin with iron in 1:1:1 ratios have also been observed (262). Iron-coordination
by siderophore and siderophore-like (pseudosiderophore) complexes is quite variable and
dependent on the structure, concentration and protonation of compounds in the
microenvironment.
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Figure 1-3: Molecular structure of representative siderophores. Structures of several
siderophores including non-ribosomal peptide synthetase (NRPS)-dependent
enterobactin, vibriobactin, yersiniabactin and pyochelin, as well as NRPS-independent
aerobactin, desferrioxamine, vibrioferrin, staphyloferrin A, and staphyloferrin B, among
others. Figure taken from (96).
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In general, three major iron-binding moieties act as coordination motifs, which
are catecholates/phenolates, hydroxamates, and (α-hydroxy-)carboxylates (Figure 1-3).
Predominantly bidentate coordination motifs employ hydroxyl groups separated by three
covalent bonds. Enterobactin employs three catecholate (ortho-dihydroxybenzene) groups
(2,3-DHB precursors) to coordinate iron with six bonds for an extremely stable structure
(Figure 1-3). In fact, most catecholate siderophores use 2,3-DHB as a precursor for
synthesis, and this compound is alone capable of coordinating iron in a 3:1 ratio. Some
bacteria even secrete 2,3-DHB as a means to attain environmental iron (264, 265).
Mammals encode an EntA (enterobactin synthesis enzyme) homolog responsible for
synthesis of 2,5-DHB (266). The structural similarity between 2,3-DHB and 2,5-DHB
affords microbial pathogens the ability to coopt 2,5-DHB as well as 2,3-DHB to attain
iron through the same transporter (Figure 1-4). Therefore the mammalian host suppresses
2,5-DHB production upon TLR stimulation with LPS (except TLRs 5 and 7) (267).
Mammalian catecholamine stress hormones are too structurally similar to 2,3-DHB and
may also promote pathogen growth (Figure 1-4). Stress hormones such as epinephrine,
norepinephrine and dopamine interact with transferrin and lactoferrin to reduce Fe3+ to
Fe2+, thereby liberating it (268). The hormones complex with the released iron in a 3:1
ratio for hexacoordinate symmetry and act as pseudosiderophores to facilitate iron
acquisition by a number of pathogens (269–271).
Hydroxamate iron-coordination motifs use a carbonyl and adjacent
aminohydroxyl group as a bidentate iron chelate. These types of siderophores are
frequently produced by fungal species, including coprogen and ferrichrome, among
others (272). Carboxylate motifs employ dual α-hydroxycarboxylates derived from citrate
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Figure 1-4: Molecular structure of iron-coordinating catecholate compounds. The
bacterial siderophore precursor 2,3-dihydroxybenzoic acid (DHBA), and the other,
mammalian-produced molecules coordinate iron with bidentate symmetry in a 3:1
catecholate compound to ferric iron ratio.
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or carboxylic acid moieties to coordinate iron in a similar manner, such as in
staphyloferrin A and achromobactin (273, 274). Many siderophores contain a
combination of the three predominant coordination motifs, including petrobactin and
aerobactin (253, 275). Multiple bi- or tridentate entities form very stable ironcoordination complexes which may appropriate iron directly from host proteins such as
transferrin, and constitute an important source of iron for invading pathogens (93, 276).

1.4.7

Siderophore transport

Systems for bacterial extracellular removal of iron from siderophores are not well known
(as they are in eukaryotes), and prokaryotes primarily transport ferric siderophores to the
cytoplasm prior to iron release. Gram-negative bacteria must import ferric siderophores
across both membranes through outer membrane receptors, Ton-channeled energy, and
PBP-permease-mediated translocation, as detailed previously. Gram-positive bacteria
employ a lipoprotein-ABC transporter for ferric siderophore acquisition (Figure 1-2).
Genetic loci for siderophore transporters are often proximal to the cognate siderophore
biosynthetic locus in the genome. Siderophore-binding proteins may exhibit some degree
of indiscrimination towards substrates. E. coli outer membrane FepA transports ferricenterobactin, 2,3-DHB and 2,5-DHB, however cannot transport corynebactin, which is
structurally similar to enterobactin but has opposite chirality, indicating a ferriccoordination chemistry is required for transport (267, 277). PBPs exhibit more plasticity
than outer membrane receptors, including FhuD which binds several hydroxamate
siderophores including ferrichrome, aerobactin, coprogen and ferrioxamine, which each
have specific outer membrane receptors (278, 279). Fhu homologs exist in Gram-positive
species as well, with the S. aureus Fhu transporter best characterized among them (280–
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282). S. aureus actually elaborates dual FhuD1 and FhuD2 lipoproteins, which both
interact with the FhuCBG transporter, although have variable substrate affinity and
plasticity (283, 284).

1.4.8

Siderophore-iron removal

Once the siderophore enters the cytoplasm, both Gram-negative and Gram-positive
bacteria employ similar means to extract the coordinated iron. Iron may be reduced and
discharged via cellular ferric siderophore reductases, although most of these are
nonspecific. Specialized enzymes are however produced to modify or degrade ferric
siderophores such to release iron through a loss of complex stability, allowing other
cellular iron-binding compounds access. Both reductive and degradative siderophore-iron
removal processes occur in E. coli. Enterobactin, which binds iron more tightly than
several hydroxamates, must be degraded by FesA prior to iron reduction and subsequent
release, whereas hydroxamate siderophores are simply kept intact and recycled externally
once iron is reduced by FhuF (285–287). An iron-sulfur cluster in FhuF mediates
reduction, lending this protein to be a prime example of an iron-regulated reductase with
specificity for a class of siderophores. Alternatively, YqjH contains a flavin adenine
dinucleotide (FAD) binding domain, interacts with siderophores and is also involved in
ferric iron reduction, with a much broader range of substrates (288). Somewhat similar
systems exist in Gram-positive pathogens. Oxidoreductase IruO binds FAD and NADPH
and helps to facilitate iron release from heme and desferrioaxamine (hydroxamate) in S.
aureus (289, 290). Nitroreductase NtrA also aids in iron release from heme in addition to
ferric-staphyloferrin A (290).
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1.4.9

Host siderophore defense and stealth siderophores

The mammalian host responds to the production and usage of siderophores by infectious
pathogens through siderophore sequestration, and limiting pathogen access to
siderophore-iron (Figure 1-1). Another important tool in the arsenal of innate immunity is
neutrophil secreted siderocalin (also referred to as lipocalin 2, 24p3, uterocalin and
neutrophil gelatinase-associated lipocalin; NGAL), released by degranulation in response
to TLR 2, TLR 4 or TLR 5 stimulation (291, 292). Siderocalin is part of the lipocalin
superfamily which share an eight-stranded β-barrel conformation forming a central cavity
for ligand-binding (293). Compared to other lipocalins, the siderocalin ligand-binding site
is relatively broad, shallow, and lined with polar and positive residues to facilitate
binding to a variety of catecholate and phenolate siderophores (294, 295). It is able to
bind ferric enterobactin with similar affinity as the E. coli outer membrane transporter
FepA (KD ~10-10 M) and therefore aptly competes for this iron source (293, 296).
Siderocalin can also sequester siderophore-like molecules including DHB and
catecholamine stress hormones (293, 297). It has been shown to be crucial for murine
protection against enterobactin-producing E.coli-induced mortality (298).
Pathogenic bacteria have evolved to counter the host response to siderophores by
enzymatic modification of these siderophores, rendering them unable to be recognized by
siderocalin, or being able to produce multiple siderophores of different class.
Siderophores able to bypass siderocalin entirely are termed stealth siderophores (Figure
1-1). The iroA gene cluster in E. coli is iron-regulated and encodes siderophoremodification machinery, specifically IroB, which decorates the DHB moieties in
enterobactin with glucose residues (298, 299). The resultant glycosylated enterobactin
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siderophore, salmochelin, is unable to be bound by siderocalin. The structure of
salmochelin had previously been elucidated from cultures of Salmonella enterica (300).
The production of another siderophore of a different class is another common strategy
among pathogens looking to bypass siderocalin-mediated immunity. In addition to
enterobactin, pathogenic E. coli strains also express the hydroxamate stealth siderophore
aerobactin (301). Various siderophores are expressed under different conditions, which
may be due to dissimilar stability of ferric-siderophore complexes in various conditions,
or availability of precursor molecules for their synthesis (302). Based on protonation of
iron-coordinating groups, ferric hydroxamates exhibit greater stability at more acidic pH
than ferric catecholates, which favor a more neutral to alkaline pH for ferric complex
stability. Carboxylates are the most efficient siderophores under low pH conditions in
which hydroxamates and catecholates would be more protonated (96). Pathogenic E. coli
that can produce up to four different siderophores have been isolated, and these are likely
to present advantages to bacterial fitness in various environments (303).
Bacillus produce the catecholate bacillibactin and catecholate-carboxylate
petrobactin as a similar means of avoiding siderocalin-mediated iron removal (304).
Bacillibactin coordinates iron via three 2,3-DHB moieties, and much like enterobactin is
also sequestered by siderocalin (293, 305). Petrobactin evades siderocalin by using
unusual iron coordination chemistry via two 3,4-DHB moieties and a citrate carboxylate
group (306, 307). While commensal and environmental isolates typically express
bacillibactin, pathogenic Bacillus isolates express petrobactin (308). Furthermore,
petrobactin expression contributes to B. anthracis growth in iron-limited media, survival
and proliferation within macrophages, and subcutaneous murine infection (309).
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Bacillibactin had little effect in these situations, however was found to play a role in iron
acquisition from insect host ferritin, further highlighting that siderophore structural
diversity contributes to fitness in diverse environments (310). Although catecholates bind
iron with greater affinity than siderophores of other respective classes, the host has
evolved to block this microbial iron acquisition mechanism using siderocalin,
necessitating for pathogenic microbes to respond with counter measures to siderocalin.

1.4.10

Heme acquisition

Heme represents the most abundant iron source within the mammalian host, with twothirds of total bodily iron content in hemoglobin within circulating erythrocytes. Many
pathogens have developed means to liberate hemoglobin from erythrocytes,
predominantly through secretion of hemolysins. Hemolysins may be cytotoxic to not only
erythrocytes but also cells of the immune system (ie. monocytes, lymphocytes,
macrophages), and exert cytotoxicity through pore formation or membrane damage (311,
312). They are often secreted in response to iron depletion or a blood environment, and
instrumental for pathogenesis (313, 314). Pathogens are able to appropriate heme-iron
from a combination of extracellular heme, heme-hemopexin, hemoglobin and
hemoglobin-haptoglobin using secreted hemophores, cell surface receptors, membrane
transporters and cytoplasmic heme-degradation proteins. The intricate architecture and
associations of heme-acquisition machinery underscores the significance of this
substantial iron pool.

1.4.11

Heme uptake by Gram-negative bacteria

Neisseria meningitidis does not secrete hemophores, although has two outer membrane
receptors for hemoproteins and is a simple starting model to describe heme acquisition by
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Gram-negative pathogens. HmbR binds heme and hemoglobin at the cell surface and
bipartite HpuAB binds hemoglobin and hemoglobin-haptoglobin (315, 316). HpuA
serves as the coordinating lipoprotein and HpuB the β-barrel outer membrane protein,
which translocate heme in a TonB-dependent manner (316). A PBP or inner membrane
heme transporter are currently undefined, although cytoplasmic oxygenase HemO
degrades heme to biliverdin to release iron (317). Pseudomonas aeruginosa is capable of
both hemophore-mediated and independent heme acquisition (Figure 1-5). β-barrel, outer
membrane PhuR binds heme and heme carrier proteins (hemoglobin, hemoglobinhaptoglobin, hemopexin) at the cell surface and transports heme across the membrane in
a TonB-depedent manner (318). Periplasmic PhuT binds heme and directs it to the inner
membrane PhuUV ABC transporter (319). Additionally, HasA is a secreted hemophore
that binds hemoglobin and hemopexin and transfers heme passively to another TonBdependent transporter, HasR (Figure 1-2) (320, 321). Inner membrane HasS interacts
with HasR to release the transcription factor HasI, which activates transcription of phu
and has genes (318). It has been proposed that Phu represents the principal heme
acquisition method, whereas HasAR, also required for optimal heme uptake, acts more-so
as an extracellular heme-sensor. Nonetheless, through either transporter heme may enter
the cytoplasm via PhuTUV, where it is bound by PhuS and relayed to HemO for
degradation (Figure 1-5) (322). It is worthy to mention Haemophilus influenzae, which is
unable to itself synthesize heme and relies on exogenous heme scavenging for its entire
supply. Like P. aeruginosa, H. influenzae is able to appropriate heme from a cohort of
host hemoproteins. HxuAB are part of a two-partner secretion system in which outer
membrane HxuB transports the HxuA hemophore to scavenge free heme and hemopexin-
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Figure 1-5: Schematic of heme acquisition by bacterial pathogens. a) Pseudomonas
aeruginosa hemophore-dependent and independent heme acquisition. Heme is imported
through PhuR in a TonB-dependent manner and shuttled through PhuTUV into the
cytoplasm. b) Staphylococcus aureus Isd-mediated heme acquisition from hemoglobin
and hemoglobin-haptoglobin (Hb-Hp). c) The Bacillus anthracis heme acquisition
machinery, including hemophores, Isd and other heme-binding proteins. Each system is
discussed in the main text. Figure is adapted from (319).
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heme (323, 324). HxuC transports heme from HxuA into the periplasm in a TonBdependent manner (325). Lipoprotein HbpA acquires heme from hemopexin, hemoglobin
and hemoglobin-haptoglobin (326). Additionally, HgpA, HgpC, and most importantly
HgpB external receptors acquire heme from haptoglobin-complexed hemoglobin and
myoglobin (327, 328). Many other proteins have been implicated for heme procurement
in H. influenzae, although their function remains to be fully elucidated (329–333).

1.4.12

Heme uptake by Gram-positive bacteria

Heme acquisition by Gram-positive bacteria is arguably just as complex as that of Gramnegatives. The S. aureus iron-regulated surface determinant (Isd) pathway of heme
acquisition from hemoglobin and hemoglobin-haptoglobin is the best characterized heme
uptake system in Gram-positive pathogens (Figures 1-2 and 1-5). For optimal
functionality, hemoprotein-binding Isd proteins must pass the thick peptidoglycan wall in
order to bind larger ligands. This is accomplished through Sortase A (SrtA), which
recognizes C-terminal LPXTG motifs and covalently attaches IsdA, IsdB and IsdH to
peptidoglycan (334). Sortase B (SrtB) is transcribed with other Isd proteins and tethers
IsdC to peptidoglycan through recognition of a NPQTN motif (335). Each sortase cleaves
peptides at either respective C-terminal recognition sequence between TG and TN
residues, and attaches the threonine C-terminal carboxyl to the peptidoglycan
pentaglycine cross-bridge (334, 336, 337). At the cell surface, IsdH binds haptoglobin,
IsdB binds hemoglobin, and IsdA binds free heme (338–340). The former two extract
heme from hemoglobin by eliciting steric strain to destabilize hemoglobin and facilitate
heme release (341, 342). Heme is passed down the Isd cascade via IsdA and IsdC cell
wall anchored proteins, with IsdC being the conduit between the external environment
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and the integral membrane heme transporter (343–345). Lipoprotein IsdE, in consort with
integral membrane IsdDF, transfers heme from IsdC across the membrane (346, 347).
Once internalized, cytosolic heme is incorportated into bacterial proteins or degraded.
Heme oxygenases IsdG and IsdI degrade heme to staphylobilin and free iron (348–350).
Although both oxygenases are upregulated in low iron conditions, IsdG undergoes
proteolytic processing for degradation in low heme conditions, signifying a differential
response to iron source availability (351, 352). The heme uptake system of B. anthracis
shares many similarities to the S. aureus Isd pathway, however also uses two secreted
hemophores (Figure 1-5). The two hemophores are the first to be described among Grampositive organisms and may be absent from others that lack the complex surface
architecture of Bacillus, including the antiphagocytic capsule and proteinaceous Surface
(S)-layers (353, 354). IsdX1 (formerly IsdJ) and IsdX2 (formerly IsdK) are secreted to
the external cellular milieu and extract heme from host hemoglobin and transfer it to
bacterial cell wall-bound IsdC (355, 356). Alternatively, sortase A-anchored, cell walllocalized HaI can also extract heme from hemoglobin, and BslK (S-layer domain
homology), which is non-covalently attached to the cell wall, transfers heme to IsdC
(357–359). Much like in S. aureus, B. anthracis IsdC funnels heme through the cell wall
towards IsdDEF, which translocates heme into the cell prior to IsdG-mediated heme
degradation (360, 361). Although B. anthracis lacks IsdH, IsdB and IsdA, it makes up for
these with its own set of heme-extraction factors (Figure 1-5). The IsdX2 hemophore has
been proposed to also function as a heme-storage protein as it can bind multiple heme
residues at once, essentially acting to slow bacterial heme acquisition, which may be
important to mitigate toxicity.
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Heme-binding proteins in the aforementioned Isd pathways have one or more
conserved near iron transporter (NEAT) domains responsible for binding and
coordinating the heme molecule (362). NEAT domains are composed of variable ~120
amino acids in domains with a highly conserved eight-stranded, antiparallel β-sandwich
fold (363, 364). Heme is bound within a hydrophobic pocket and coordinated by tyrosine
residues in an YXXXY motif (364, 365). IsdB and IsdH contain two and three NEAT
domains, respectively, whereas IsdA and IsdC contain one (364, 366–368). NEAT
domains may vary in functionality due to differences in primary sequence or overall
domain structure such to facilitate hemoprotein-binding, heme extraction or intra- or
inter-protein heme transfer. IsdB-NEAT1 (N1; N-terminal) binds hemoglobin or
hemoglobin-haptoglobin whereas N2 binds heme (342). IsdH-N1 and N2 bind
hemoglobin-haptoglobin and N3 binds heme (369). Hemoglobin-binding is mediated
through a FYHYA motif by IsdB-N1 and IsdH-N2, or a YYHFF configuration for IsdHN1 (367, 369, 370). On the other hand, B. anthracis IsdX1, HaI and BslK each have one
NEAT domain and IsdX2 has five (191, 319). Interestingly, IsdX2-N2 is unable to bind
heme due to a histidine replacing the second tyrosine in the heme-binding motif, yet this
domain interacts with hemoglobin to facilitate heme capture by other NEAT domains
(371, 372). The structural basis of heme extraction and transport between B. anthracis
heme acquisition proteins is not fully detailed as of yet. NEAT-domain containing
proteins have been characterized in a number of Gram-positive pathogens including
Streptococcus pyogenes, L. monocytogenes, and S. lugdunensis (373–376).
Bioinformatics analysis indicates that NEAT-domain containing proteins may be widely
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distributed among Firmicutes and present in both pathogenic and non-pathogenic
organisms, although these must be characterized to elucidate their functions (363).
Corynebacterium diphtheriae uses non-NEAT mediated mechanisms to acquire
heme through HmuTUV, HtaABC and ChtABC/CirA. HmuTUV bear sequence
homology to heme transporters in Gram-negative pathogens, including HmuTUV in
Yersinia pestis (377–379). Lipoprotein HmuT is capable of binding heme and
hemoglobin and thought to relay heme into the cell through the HmuU permease and
HmuV ATPase (377). It was later discovered that genes proximal to hmuTUV are also
involved in heme acquisition. htaA is encoded with hmuTUV and htaBC are encoded in
an adjacent locus (380, 381). HtaA and HtaB both contain N-terminal secretion signals
and C-terminal transmembrane domains. While HmuT and HtaB are predominantly
found in the cytoplasmic membrane, the majority of HtaA is extracellular (380). HtaA is
able to interact with hemoglobin and may function as an extracellular hemophore (382).
The model includes heme extraction from hemoglobin by HtaA, and then relay to HtaB
and further to HmuT prior to translocation via HmuUV (382). Binding of heme is
facilitated by an N-terminal histidine and C-terminal tyrosine on HmuT, whereas HtaA
and HtaB employ unique conserved regions (CR) of ~150 amino acids to bind heme or
hemoproteins (382, 383). HtaA has two CR domains and CR2 is the predominant heme
and hemoprotein-binding domain with conserved tyrosine and histidine residues critical
for binding. HtaB has one CR domain with high affinity for heme, and can accept heme
from HtaA (382). Complete deletion of the hmu-hta locus reduces, but does not
completely abrogate growth with heme as a sole iron source, and chtAB and cirA chtC
operons were further identified as important for heme acquisition. All four of the encoded
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proteins are surface-exposed and ChtA, ChtB and ChtC each have one CR domain and
are all capable of binding heme and hemoglobin (384). ChtA and ChtC, much like HtaA,
are able to bind hemoglobin-haptoglobin, whereas ChtB appears to be functionally
redundant to HtaB (384, 385). The interplay between these functionally redundant
systems has not been investigated in detail, although a combination of HtaA, ChtA and
ChtC may function to bind hemoglobin-haptoglobin, extract heme, and relay it to HtaB or
ChtB and further to HmuTUV (385). Internalized heme is degraded by the canonical
heme oxygenase HmuO (386). Factors affecting cell wall remodeling to facilitate surface
exposure of the exposed proteins, such that they remain membrane-associated and also
bind the larger substrates (ie. hemoglobin-haptoglobin) are unknown. The contributions
of these heme acquisition mechanisms to survival and growth of C. diphtheriae in the
host remain undefined.

1.4.13

Transcriptional regulation of iron acquisition mechanisms

Iron limitation serves as a sensory cue that triggers global changes in the protein
expression profile of a pathogen to better adapt to starvation conditions that would be
encountered within the host. Key nutrient acquisition mechanisms and virulence factors
are expressed to better make use of the shifted environmental conditions for growth and
evasion of host defense strategies. Transcriptional regulators are primary mediators of the
observed changes, acting to promote or deter expression of specific genes. The ferric
uptake regulator (Fur) is the classical, canonical iron responsive transcriptional regulator
in prokaryotes. Several species have structurally and functionally analogous regulators,
including DtxR in C. diphtheriae and MtsR in S. pyogenes (381, 387, 388). The
homodimeric metalloproteins function predominantly as repressors of iron-responsive
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genes. Each monomer contains a ~120 amino acid winged-helix DNA-binding domain
and a regulatory metal-binding carboxyl moiety that enables dimerization upon
corepressor (ferrous iron) binding (389–391). When cellular iron is replete and exceeds
that required for proper functioning of iron-containing metalloproteins, ferrous iron
associates with each subunit of the dimer and facilitates a conformation change to allow
DNA binding (392). The target is a 19-bp sequence in the operator/promoter region of the
target gene locus termed the Fur box. The recognition sequence is an AT-rich inverted
palindromic repeat consisting of 9-bp with a 1-bp separation (389, 390, 393). Binding of
Fur to the Fur box restricts spatial access of RNA polymerase to the promoter region,
blocking transcription. Decrease of intracellular iron levels cause Fe2+ dissociation from
Fur and release of DNA for derepression of genes including those for acquisition of
various iron sources, in addition to many other virulence factors (394–396). Fur is also
known to upregulate genes directly, and indirectly through repression of small silencing
RNA molecules (397, 398).
The redox capability of iron confers on Fur a large role in pathogen defense
against oxidative and nitrosative stress encountered in the host. PerR (or functionally
equivalent OxyR or OhR) is a Fur paralog that plays a central role in the response to
oxidative stress and sensing the Fe/Mn ratio in the bacterial cell (399). Both of these ions
may be coordinated in the regulatory site of the zinc-containing metalloprotein (400).
Iron and manganese compete for binding, and Fe2+-PerR is greatly more sensitive to
oxidation than Mn2+-PerR and thought to be responsible for sensing oxidative stress
(401). Like Fur, metal binding to PerR facilitates binding to the promoter region of genes
in the PerR regulon for repression (402). Oxidation of Fe2+-PerR leads to derepression of
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target genes, whereas Mn2+-PerR is insensitive to oxidation (403). Additionally, metal
selectivity influences the subset of genes regulated, where Fe2+-PerR only represses a
subset of genes in the regulon most critical for response to oxidative stress (402).
Furthermore, Fur is regulated by PerR and upregulated by oxidative stress, indicating
crosstalk between iron and manganese homeostasis with stress response, which adds to
the complexity of how dynamic environmental signals impact on the bacterial
transcriptome through sensor proteins with varying specificity and sensitivity (402, 404–
406).

1.5 Staphylococcus spp.
1.5.1

The genus Staphylococcus

The Staphylococcus genus includes 51 Gram-positive bacterial species. Most reside on
the skin and mucous membranes of their mammalian hosts and remain harmless
commensals. Several species are capable of opportunistic infection in humans and are of
particular clinical consequence. S. saprophyticus is a leading cause of uncomplicated
urinary tract infections (407). S. epidermidis is found ubiquitously on the skin of many
mammals and may form dense biofilms on indwelling biomaterials (ie. catheters,
prostheses), making it a common nosocomial pathogen associated with device-related
infections (408, 409). S. lugdunensis is also a ubiquitous skin commensal although it is
gaining notoriety for causing serious infections, including skin and soft tissue infections
(SSTIs), osteomyelitis, pneumonia, meningitis, and particularly aggressive endocarditis
(410–412). S. aureus is the most well known staphylococcal species, responsible for
causing a broad spectrum of infections which include the clinical manifestations
mentioned for S. lugdunensis (413). S. aureus is most commonly found in the anterior
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nares, permanently in ~20% of the population and transiently in another ~60% (414).
Although only present in a subset of the population, S. aureus is responsible for the
majority of staphylococcal clinical manifestations requiring hospitalization.
S. aureus is distinguished from the former three (and other) staphylococci as
coagulase-positive, in that it secretes abundant coagulase. Coagulase binds to and
activates prothrombin in serum to convert fibrinogen to fibrin and cause clotting (415). S.
lugdunensis does not secrete soluble coagulase, although does produce a membranebound coagulase (clumping factor) which elicits a similar positive result in a slide
coagulation test (416). Although cases are rare, several common veterinary species of
coagulase-positive staphylococci are also able to cause disease in humans, further
reducing the specificity of coagulase analysis as a diagnostic tool (417–419). Despite
somewhat inexact genotyping based on phenotype, Staphylococcus species are still (as of
now) classified as coagulase-positive (CPS) or coagulase-negative (CNS).

1.5.2

Staphylococcus aureus pathogenesis

The large number of S. aureus-associated clinical manifestations has garnered the
bacterium considerable attention among researchers, and it is the most widely studied
Staphylococcus species. While traditionally thought of as a nosocomial pathogen, several
strains have gained notoriety for causing disease in otherwise healthy individuals in
community-acquired infections (420). The ability to colonize many bodily tissues endows
the pathogen the ability to cause many various disease states, which may lead to host
fatality (413). The success of S. aureus to colonize and cause pathogenesis in the host is,
in part, attributed to its vast arsenal of virulence factors. Among the best studied include
compounds involved in tissue attachment (host extracellular matrix-binding, clotting,
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biofilm formation; clumping factors, coagulase, DNA and polysaccharide-laden
biofilms), immune evasion (inhibition of complement, immune cell chemotaxis and
phagocytosis; staphopains, aureolysin, protein A), causing host cell damage (numerous
pore-forming toxins; Panton Valentine leukocidins, α-hemolysin), mitigation of
destruction (resistance to lysozyme, antimicrobial peptides and oxidative damage; OatA,
MprF, SodA and SodM) and overcoming nutritional immunity (vital nutrient acquisition;
staphyloferrin siderophores, Isd, Mnt). For more comprehensive reviews of S. aureus
virulence determinants, consult (191, 421–424).

1.5.3

Staphylococcus aureus response to iron withholding

The S. aureus metabolome changes quite drastically when the bacterium enters the host
bloodstream. Changes in environmental nutrients govern these metabolic shifts.
Glycolysis is upregulated, whereas tricarboxylic acid (TCA) cycle activity is
downregulated through carbon catabolite repression as an iron-sparing response to take
advantage of increased glucose, and redistribute iron from the TCA iron-sulfur cluster
containing proteins (425–427). The iron-sparing response upregulates glycolytic and
fermentative pathways, generating ATP independently of respiration, and accumulates
acidic byproducts (lactate) in the extracellular milieu (425). The decreased pH may
promote dissociation of iron from host proteins such as transferrin and lactoferrin.
Iron depletion in the host confers a harsh environment and influences S. aureus
pathogenesis via Fur. The iron-responsive regulator coordinates expression of many
notable exoproteins including hemolysins, cytotoxins and immunomodulatory proteins, in
addition to genes for iron procurement (313). S. aureus produces and secretes the stealth
siderophores staphyloferrin A (SA) and staphyloferrin B (SB), which bind iron
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specifically (428, 429). Staphylopine is a recently identified metallophore able to
associate with several metal ions including iron, zinc, nickel, cobalt and copper.
Staphylopine-metal binding differs among varying environmental conditions and
bacterial growth status, and relevance for in vivo colonization and virulence is yet
undetermined (430). S. aureus elaborates Isd proteins to acquire heme-iron from
hemoglobin-haptoglobin, as well as transporters for acquisition of xenosiderophores with
hydroxamate (Fhu) or catecholamine (Sst) moieties (271, 280, 340). Heme is the most
abundant source of iron within the mammalian host and the preferred iron source of S.
aureus (431, 432). A transcription factor (SbnI) encoded on the SB biosynthetic operon
has been shown to modulate siderophore production and repress SB biosynthetic genes in
the presence of heme (432). Interestingly, the staphylococcal siderophores are produced
in distinct infection conditions, where staphyloferrin A is predominantly produced during
subcutaneous infection whereas staphyloferrin B in glucose-rich environments such as in
circulation (191, 433).

1.5.4

Staphyloferrin A and staphyloferrin B

The vast majority of Staphylococcus spp. produce SA (434). The biosynthetic operon
consists of sfaABC and sfaD, transcribed divergently (Figure 1-6). The siderophore is
produced by NRPS-independent synthetases. The SfaD synthetase condenses a citrate
molecule with the δ-amine of D-ornithine as the rate limiting step, and SfaB further
condenses another citrate molecule to the α-amine of the precursor (428). SfaC is a
putative amino acid racemase that converts L-ornithine to D-ornithine, and SfaA is a
major facilitator superfamily (MFS) efflux pump responsible for SA secretion (435, 436).
SA coordinates Fe3+ using α-hydroxycarboxylate groups on the internal citrate moieties
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Figure 1-6: Staphylococcus aureus siderophore transporters. Staphyloferrins A (SA)
and B (SB) are synthesized by products of the sfa and sbn operons, respectively, and
ferric-SA and ferric-SB are internalized through Hts and Sir transporters, respectively.
Siderophores bearing hydroxamate or catechol moieties are transported by Fhu and Sst
ABC transporters, respectively. Genes are colour-coded for distinction of protein
products: yellow, siderophore synthetase; white/gray, integral membrane protein (for
siderophore secretion or internalization); blue, lipoprotein receptor; peach/green, ATPase.
Figure is adapted from (437).
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for 6 coordination sites (438). The ABC transporter for SA uptake is encoded on hts
genes situated next to genes for SA biosynthesis (Figure 1-6) (273). HtsA is the
lipoprotein component that facilitates SA-binding and transfer through the HtsBC
permease for translocation via energy generated by the FhuC ATPase (273, 439). The
HtsA SA-binding site is a charged pocket lined with basic arginine residues particularly
adept to bind the anionic siderophore (438, 440).
SB (formerly known as staphylobactin) is produced by several staphylococcal
species (429, 441, 442). The biosynthetic operon contains nine genes, sbnA-I, including
several for NRPS-independent synthesis of SB (Figure 1-6). SbnA uses O-phospho-Lserine and L-glutamate to generate an intermediate product, which is hydrolyzed by SbnB
to produce L-2,3-diaminopropionic acid (DAP) and α-ketoglutarate precursors for SB
biosynthesis (443). SbnG is a novel citrate synthase that catalyzes citrate production from
oxaloacetate and acetyl-CoA, thus compensating for the downregulation of CitZ (TCA
cycle citrate synthase) during the iron-sparing response (433, 444). Citrate and DAP are
condensed via SbnE, which is further processed by SbnH to decarboxylate a carboxyl
group on the DAP end of intermediary product. SbnF catalyzes the condensation of
another DAP molecule with the prochiral carbon of the citrate moiety on the precursor,
and finally SbnC condenses the diaminoethane group on the precursor with an αketoglutarate (429). The complete SB molecule is secreted via the SbnD MFS efflux
pump, or an alternate yet to be determined transporter (436). As mentioned previously,
the final encoded protein, SbnI, is involved in regulation of siderophore production (432).
Carboxylate SB coordinates Fe3+ in hexadentate fashion using a nitrogen and five oxygen
atoms (445). Ferric-SB is transported through encoded products of the sirABC operon,
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transcribed divergently from the sbn operon (Figure 1-6). Lipoprotein SirA binds to SB
with unique coordination compared to SA-HtsA binding, with different conformational
shifts upon substrate-binding and few conserved contacting residues between SirA and
HtsA for coordinating their respective carboxylate siderophores (445). Ferric-SB is
passed through SirBC and internalized via energy generated by the FhuC ATPase (282).
sfa, hts, sbn and sir loci all have Fur boxes in their promoter regions and are indeed ironregulated (273, 429, 437).

1.5.5

Xenosiderophore acquisition by Staphylococcus aureus

S. aureus cannot synthesize, yet is able to transport exogenously-produced hydroxamate
siderophores (Figure 1-6). In the case of this transporter, either of two lipoproteins
FhuD1 and FhuD2 are responsible for substrate recognition, binding of hydroxamate
siderophores, with FhuD2 exhibiting both a broader substrate specificity and greater
binding affinity for substrates (281, 283). These lipoproteins shuttle various hydroxamate
substrates through the FhuBG permease, via energy derived from the associated FhuC
ATPase (280). The FhuC ATPase required for hydroxamate transport is the same that is
required for transport of SA and SB. The Fhu transporter in S. aureus is also relevant to
medical practice, as chelation therapy for iron overload disorders (such as thalassemia
and hemochromatosis) frequently use hydroxamate chelators as treatment, including
DesferalTM (Novartis), which may exacerbate infection-favouring conditions (284).
S. aureus is also capable of using catechols for growth, although does not produce
any catechol siderophore (Figure 1-6). The sstABCD operon has been described as a
catechol transporter in S. aureus. The SstD lipoprotein functions in association with the
SstAB membrane permease and SstC ATPase to transport host-produced catecholamine
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stress hormones (ie. epinephrine, norepinephrine, dopamine, L-DOPA) as a source of
iron, as these molecules are able to liberate iron from host proteins such as transferrin
(271). The sst locus has a Fur box in the promoter region and has been shown to be ironregulated (446). Further description of the method in which iron is released from SA, SB,
hydroxamates and catecholamines is warranted, as well as any regulatory effects these
compounds may have. It is plausible that since the Sst transporter uses a different ATPase
than the other siderophore acquisition machinery, it may have other, yet to be determined
functions in addition to iron acquisition.

1.5.6

Staphylococcus aureus heme-iron acquisition

Heme acquisition by S. aureus is mediated by the Isd system detailed in the earlier
section ‘Heme uptake by Gram-positive bacteria’ (see Figure 1-5). The sortase-A
anchored Isd proteins are transcribed separately from the core of the system. IsdH, IsdB
and IsdA are each transcribed separately from the isdCDEF srtB isdG operon, with isdA
and isdB transcribed divergently and separately from the other. isdH and isdI are
dissociated in the genome from the other isd genes. The Isd system is a high-affinity
heme acquisition mechanism that allows growth with low nanomolar concentrations of
heme/hemoglobin typical of physiological circulatory conditions (447). At
supraphysiological heme-iron concentrations (>50 nM), the Isd system becomes less
relevant and another, yet unidentified heme-iron acquisition system permits growth of isd
deletion mutants (447, 448). Non-Isd heme-iron acquisition is believed to play a larger
role in prolonged infection states in which hemolysis/necrosis has taken place, although
this notion remains to be validated. Nevertheless, Isd proteins are highly upregulated in
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blood and serum and S. aureus single gene isd deletion mutants are attenuated for growth
in mammalian infection models (339, 351, 447, 449, 450).

1.5.7

Staphylococcus lugdunensis

S. lugdunensis was first described in 1988, and named after where it was isolated, in
Lyon, France (451). Despite being able to cause debilitating disease reminiscent of S.
aureus, S. lugdunensis remains an underappreciated pathogen, likely due to its more
recent emergence. The ubiquitous skin commensal largely inhabits the lower extremities,
including the groin region and perineum (452). It is responsible for both nosocomial and
community-acquired infections and while most clinical manifestations are SSTIs
(55.4%), 17.4% of infections are of blood and vascular catheter origin (453). Strikingly,
rates of required surgery for S. lugdunensis-associated infective endocarditis (IE) surpass
that of S. aureus IE (70% vs. 36.9%), and the mortality rate of S. lugdunensis-associated
IE (50%) is much greater than that of S. aureus (14.5%) and S. epidermidis (20%) (454,
455). Nearly half of infected patients have no comorbidities, indicating S. lugdunensis is
able to cause disease in otherwise healthy individuals (411). In addition to skin trauma,
many reports detail individuals who undergo surgical procedures including vasectomy
and kidney transplant and acquire S. lugdunensis IE soon-after (456–459). Although S.
lugdunensis infections typically occur at lower frequency than S. aureus, the true burden
may be underestimated due to S. lugdunensis isolates producing clumping factor
(membrane-bound coagulating protein), which elicits positive slide coagulase and/or
latex agglutination results in the clinic, leading to misidentification.
The enigmatic S. lugdunensis exhibits elevated virulence compared to other CNS,
yet genome sequence analysis indicates a lack of most of the virulence factors present in
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S. aureus. How then is this odd, recently discovered CNS able to cause severe disease
akin to or more virulent (for IE) than other staphylococci? Data on molecular
determinants for S. lugdunensis pathogenesis is scarce, and CNS typically only have a
few virulence determinants (460). In addition to fibrinogen binding protein (Fbl,
clumping factor ClfA homolog), there is limited information on a yet uncharacterized von
Willebrand-binding protein (vWbl), and S. lugdunensis synergistic hemolysins (SLUSH
peptides) (461–466). SLUSH A, B and C are short β-type phenol soluble modulin-like
peptides that function analogously to δ-toxin and exhibit cytotoxic effects on host cells
(466, 467). SLUSH peptides also attract and activate neutrophils via formyl peptide
receptor 2 (Fpr2) (468, 469). About half of S. lugdunensis clinical isolates lack SLUSH
genes, whereas all isolates have genes for β-hemolysin and hemolysin III (ie.
sphingomyelin phosphodiesterase) (470). Interestingly, 5% of isolates are non-hemolytic,
and these may or may not contain SLUSH gene sequences (466, 470). The latter two
mentioned hemolytic factors have yet to be investigated, and the reason for some isolates
being non-hemolytic is perplexing given their genetic profiles to bear genes for
expression of putative hemolytic proteins. Recent advancements in S. lugdunensis genetic
manipulation has allowed for more detailed studies into the organisms biology. S.
lugdunensis is the only other staphylococcal species to contain a region with similar
sequence and organization to S. aureus isd, albeit with differences and most identity
occurring within protein NEAT domains. S. lugdunensis IsdB has been shown to bind
human hemoglobin and hemoglobin-haptoglobin, and isd genes are required for growth
with hemoglobin as a sole iron source (376). IsdG has also been shown to degrade heme
to release iron (471). In addition to the ability to accept heme from IsdB, IsdC is
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important for biofilm formation under low-iron growth conditions (376, 472). Further
detailing the S. lugdunensis Isd system is warranted, as well as other potential virulence
determinants.

1.6 Objective and inquiries
S. lugdunensis is an emerging pathogen able to cause destructive infections with high
rates of mortality even with therapeutic surgical intervention. There is a lack of described
virulence factors for this staphylococcal species, fueling our interest to study this curious
microbe. Prior to this study, genome sequences of two isolates had been recently
published, and would aid us in ascribing biological functions to several genomic regions
of interest (473, 474). During the course of this study, there were two publications that
evaluated S. lugdunensis virulence in mammalian endocarditis models, and only Sortase
A was shown as a virulence factor in the host (475, 476). Mechanisms of iron acquisition
were largely undefined, and the Isd system, several components of which were well
characterized, was not described completely. The objective of this study was to describe
the host-iron acquisition strategies of S. lugdunensis. Experimental research was aimed to
address the following inquiries:
1) Does S. lugdunensis produce a siderophore – likely one of the two common
staphylococcal siderophores (SA and/or SB)?
2) What siderophores is S. lugdunensis capable to acquire, and can it acquire hostproduced catecholamine stress hormones as sources of iron?
3) What is the impact of siderophore and/or heme acquisition for colonization and
pathogenesis in the host?
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Chapter 2
Staphyloferrin siderophore and heme acquisition by
Staphylococcus lugdunensis

Significant portions of this chapter have previously been peer-reviewed and published in:
Brozyna, J. R., Sheldon, J. R., and D. E. Heinrichs. 2014. Growth promotion of the
opportunistic human pathogen, Staphylococcus lugdunensis, by heme, hemoglobin, and
coculture with Staphylococcus aureus. MicrobiologyOpen. 3(2): 182-95.
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2.1 Introduction
In 1988, Staphylococcus lugdunensis was described as a new species of coagulasenegative staphylococcus (CoNS), isolated from a human clinical specimen (1). It is now
widely considered to be an emerging pathogen with uncharacteristically elevated
virulence in comparison with other members of the CoNS (2). In addition to being a skin
commensal, S. lugdunensis is responsible for both nosocomial and community-acquired
infections that may include skin and soft tissue infections (SSTIs), pneumonia,
meningitis, and endocarditis (3–6). While the most common clinical manifestation of S.
lugdunensis infection is SSTIs (55.4%), blood infections and those associated with
vascular catheterization accounted for a notable 17.4% of diagnoses (7). Strikingly, the
mortality rate of S. lugdunensis associated endocarditis may reach up to 50% (3). Despite
that S. lugdunensis is gaining notoriety as an atypically virulent CoNS, the true burden of
S. lugdunensis infection is likely underestimated. Since most S. lugdunensis isolates are
hemolytic, and are capable of producing a membrane-bound clumping factor (coagulant),
it is possible that many S. lugdunensis infections are misinterpreted as being caused by S.
aureus (8, 9). Moreover, nearly half of patients infected with S. lugdunensis appear to
have no comorbidities, indicating that this underappreciated pathogen is able to cause
infection in the absence of overt susceptibility (5).
Iron is an essential nutrient for most pathogenic bacteria, including the
Staphylococci, and represents a significant growth-limiting nutrient in the host (10).
Virtually all host iron is bound to glycoproteins such as transferrin, ferritin, and
lactoferrin (11), or is in complex with heme in hemoproteins. Hemoglobin iron accounts
for up to 75% of total host iron, the vast majority of which is found within circulating
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erythrocytes (12). To establish infection, pathogens must circumvent host iron
sequestration strategies, and therefore, by extension, must possess elaborate iron
acquisition mechanisms in order to obtain this limited nutrient. Frequently, these iron
uptake strategies involve either the acquisition of heme contained in hemoglobin, or the
removal of transferrin-bound iron through the secretion of siderophores (13).
Siderophores are small molecules (commonly less than 1000 Da) capable of binding
ferric iron with high affinity, and delivering iron back to the cell via surface localized and
membrane-embedded receptor proteins.
Much of our molecular understanding of iron acquisition processes in the
staphylococci comes from studies in S. aureus. The iron-regulated surface determinants
(Isds) were first discovered in S. aureus (14, 15). The Isd system is now fairly-well
characterized, and is constituted by a series of proteins that, together, are capable of
extracting heme from hemoglobin at the bacterial cell surface, and relaying heme across
the cell wall, through the cytoplasmic membrane, and into the cytoplasm where it is
degraded to release iron for use in cellular processes (16, 17). S. aureus also produces
two siderophores, staphyloferrin A (SA) and staphyloferrin B (SB), which are
synthesized by gene products encoded from within the sfa and sbn genetic loci,
respectively (18, 19). S. aureus internalizes ferric-SA and ferric-SB using the ABC-type
transporters HtsABC and SirABC, respectively, encoded by genes found adjacent to the
cognate biosynthetic loci (18, 20–22). S. aureus strains mutated for staphyloferrin
production are severely restricted for growth in the presence of transferrin or animal
serum (23, 24).
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Investigations of the molecular mechanisms that contribute to the virulence of S.
lugdunensis are in their infancy. Few mutants have, as of yet, been constructed and
characterized, and even fewer tested in animal models. In one recent study it was
demonstrated that, in S. lugdunensis, sortase A, responsible for the anchoring of LPXTGcontaining proteins to the cell wall, was required for full virulence in a rat endocarditis
model (25). Interestingly, the genome sequencing of two strains of S. lugdunensis,
HKU09-01 and N920143, revealed that this species is unique among the CoNS in that it
encodes an Isd system (26–29) and, moreover, in strain HKU09-01, the isd locus is
tandemly duplicated. Work led by T. Foster's group has revealed that the isd system in
strain N920143 is functional, contributing to the strain's use of hemoglobin as an iron
source (29).
In this study, we investigate iron uptake mechanisms in S. lugdunensis through
characterizing the role of the S. lugdunensis strain HKU09-01 isd locus in heme and
hemoglobin utilization, as well as characterizing this species for the ability to produce
and utilize staphyloferrins. We demonstrate that a mutant lacking isd is severely impaired
for growth using heme and hemoglobin as a sole iron source, especially at nanomolar
heme and hemoglobin concentrations. Moreover, we show that S. lugdunensis grows
poorly in serum and in the presence of transferrin owing to a lack of detectable
siderophore production. We further demonstrate that while S. lugdunensis cannot produce
staphyloferrins, it encodes the transporters for their uptake and these transporters are
functional, leading to the notion that S. lugdunensis may appropriate staphyloferrins from
other staphylococcal species to augment its growth. In support of this, we show that

104

growth of iron-restricted S. lugdunensis is significantly enhanced in co-culture with
staphyloferrin-producing S. aureus, in an hts- and sir-dependent manner.

2.2 Experimental procedures
2.2.1

Bacterial strains and growth conditions

Bacterial strains and plasmids used in this study are summarized in Table 2-1. For all
routine manipulations, Escherichia coli DH5α was grown in Difco Luria-Bertani broth
(LB, BD Diagnostics) or on LB agar (LBA). S. lugdunensis and S. aureus strains were
cultured in tryptic soy broth (TSB, BD Diagnostics) or on TSB agar (TSA). Antibiotics
were used at the following concentrations: 100 µg mL-1 ampicillin for E. coli selection;
10 µg mL-1 chloramphenicol for S. lugdunensis selection. For subsequent experiments, S.
lugdunensis and S. aureus were grown in several different iron-restricted media as
detailed, (i) Tris-minimal succinate broth (TMS) (30); (ii) TMS treated with Chelex-100
resin (Bio-Rad) for 24 hours at 4°C (C-TMS); (iii) an 80:20 mixture of C-TMS to
complement-inactivated horse serum (Sigma Aldrich); or (iv) RPMI media 1640 (Gibco)
reconstituted from powder and supplemented with 1% w/v casamino acids (RPMIC,
Difco) and 1 µM of the iron chelator ethylenediamine-di(o-hydroxyphenylacetic acid)
(EDDHA, LGC Standards GmbH). All bacteria were cultured at 37oC, shaking at 200
rpm, unless otherwise indicated. All media and solutions were prepared with water
purified through a Milli-Q water purification system (Millipore).

2.2.2

Generation of isd-sir and htsABC mutants in S. lugdunensis

Primer sequences used for the construction and complementation of S. lugdunensis
mutants can be found in Table 2-1. Allelic replacement was performed as previously
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Table 2-1: Bacterial strains, plasmids and oligonucleotides used in this study.
Bacterial strain,

Descriptiona

plasmid or

Source or
reference

oligonucleotide
Strains
E. coli
DH5α

φf80dlacZΔM15 recA1 endA1 gyrAB thi-1

Promega

hsdR17(rK− mK−) supE44 relA1 deoR Δ(lacZYAargF)U169
S. lugdunensis
HKU09-01

Human skin infection isolate

(28)

H2710

HKU09-01 Δisd-sir

This study

H2773

HKU09-01 Δhts

This study

H2774

HKU09-01 Δisd-sir Δhts

This study

Prophage-cured laboratory strain; rK− mK+;

(31)

S. aureus
RN4220

accepts foreign DNA
RN6390

Prophage-cured laboratory strain

(32)

H1324

RN6390 Δsbn::Tet; TetR

(23)

H1661

RN6390 Δsfa::Km; KmR

(23)

H1649

RN6390 Δsbn::Tet Δsfa::Km; TetR KmR

(23)
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H306

RN6390 ΔsirA::Km; KmR

(23)

H1448

RN6390 Δhts::Tet; TetR

(23)

E. coli/Staphylococcus shuttle vector allowing

(33)

Plasmids
pKOR1

allelic replacement in staphylococci
pKOR1Δisd-sir

pKOR1 plasmid for deletion of duplicated genetic This study
region encompassing isd and sir

pKOR1Δhts

pKOR1 plasmid for in-frame deletion of htsABC

This study

pRMC2

E. coli/Staphylococcus shuttle vector: ApR CmR

(34)

pRMC2::sir

pRMC2 derivative for sirABC expression; CmR

This study

pRMC2::hts

pRMC2 derivative for htsABC expression; CmR

This study

Oligonucleotidesb,c
Purpose

Sequence (5'-3')

Primers for generating (AttB1)-isdUF:GGGGACAAGTTTGTACAAAAAAGCAGGCT
upstream and
downstream
recombinant regions
for Δisd Δsir using

CTACCACTGACAGCAACGGCAAT
isdUR: CTCATTGCGATTCCTTCCTTCG
isdDF:Phos/AGCACAGATAGGAGTTCATTTGCATGTA

pKOR1
(AttB2)-isdDR:GGGGACCACTTTGTACAAGAAAGCTGGGT
AGATGCGCCTTGGATTTGACAC
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Primers for generating (AttB1)-htsUF:GGGGACAAGTTTGTACAAAAAAGCAGGCT
upstream and
downstream
recombinant regions
for Δhts using

ATTCCAGTATGTTGCCAC
htsUR: AACAGTAGCCCAATGATAC
htsDF: Phos/AGTAGGTGTCATAATAGC

pKOR1
(AttB2)-htsDR:GGGGACCACTTTGTACAAGAAAGCTGGGT
TACTGGTAATGAGCACTC
Primers for cloning
sirABC into pRMC2
for complementation

Primers for cloning
htsABC into pRMC2
for complementation
a

XhoI-sirF: GATCCTCGAGTACTGCTCCAAAATCCCC
EcoRI-sirR: GATCGAATTCTTTAGCGTGCGGTATGTC

KpnI-htsF: GATCGGTACCAAGCACTAACCCAGTCAATG
SacI-htsR: GATCGAGCTCCTAAACAATCCCCATAAAGC

ApR, CmR, KmR and TetR; resistance to ampicillin, chloramphenicol, kanamycin and

tetracycline, respectively.
b
c

Restriction sites for cloning are underlined.
Phos/ denotes a 5' phosphate on the primer.
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described, using the plasmid pKOR1 (33). In brief, 500 - 1,000-bp DNA fragments were
amplified from the genomic regions upstream and downstream of the tandem-duplicated
isd-sir locus (Figure 2-1B) using the primers isdUF and isdUR, and isdDF and isdDR,
respectively. The amplicons were cloned into pKOR1, generating pKOR1Δisd-sir.
Similarly, the plasmid pKOR1Δhts for the in-frame deletion of htsABC (Figure 2-1A)
was constructed by amplifying 500 - 1,000-bp DNA fragments flanking the start and stop
codons of the operon using primers htsUF and htsUR, and htsDF and htsDR. The vectors
were passaged through S. aureus RN4220 before introduction into S. lugdunensis
HKU09-01 by electroporation. The strains HKU09-01 Δisd-sir (H2710) and HKU09-01
Δhts (H2773) were generated using the methodology for pKOR1 (29, 33), and
introduction and recombination of pKOR1Δhts with H2710 was used to produce the isd,
sir, hts-deficient strain H2774. Chromosomal deletions were confirmed through
sequencing of PCR amplicons generated from across the deleted regions.

2.2.3

Complementation of sir and hts mutations

For complementation of the S. lugdunensis sirABC mutation, primers XhoI-SirF and
EcoRI-SirR were used to amplify the wild-type sirABC operon, including its native
promoter. The fragment was cloned into pRMC2 generating pRMC2::sir. The htsABC
complementation vector pRMC2::hts was similarly created using the amplicon generated
with XhoI-HtsF and KpnI-HtsR, again including the native promoter for htsABC.

2.2.4

Bacterial growth curves

Single, isolated S. aureus and S. lugdunensis colonies, taken from TSA plates after
overnight incubation, were resuspended in 120 µL C-TMS and 100 µL of this suspension
was used to inoculate 2 mL C-TMS. These cultures were then incubated at 37°C for at
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Figure 2-1: Physical maps of the sfa-hts and isd loci in Staphylococcus lugdunensis.
(A) Staphyloferrin A (SA) biosynthetic and uptake locus. Shown is the homologous locus
in S. aureus versus that which is present in all sequenced genomes of S. lugdunensis.
Note that the SA biosynthetic locus in S. lugdunensis carries a deletion that eliminates
two genes completely (sfaA and sfaD), along with the promoter for the remaining two
genes (sfaB and sfaC). The deleted region is indicated between the dashed lines. Asp23,
alkaline shock protein 23. (B) Shown is the ~65-kb region of the S. lugdunensis strain
HKU09-01 genome (spanning orfs SLGD_00056 to SLGD_00116) with the tandemly
duplicated isd-sir locus. The duplicated region is shown between the dashed vertical
lines. Abbreviations are as follows, with predicted or hypothetical functions: ABC,
component of an ATP-binding cassette transporter; ATP-A,B,C, K+-ATPase components
A, B, and C, respectively; mem, membrane protein; FMN, FMN binding protein;
NAT, N-acetyltransferase; marR, MarR-type regulator; hyp, hypothetical; Red, reductase;
Pase, phosphatase.
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least 4 hours until OD600 was approximately 1. The cultures were subsequently
normalized to an OD600 of 1 and 1 µL was added to 200 µL aliquots of 80:20 CTMS:horse serum growth medium. For iron replete conditions, 100 µM FeCl3 was
included. Chloramphenicol was added for strains harbouring pLI50, pRMC2 or their
derivatives. Cultures were grown with constant shaking at medium amplitude in a
Bioscreen C machine (Growth Curves) at 37oC. OD600 was measured every 15 min,
however for graphical clarity, measurements at 4-hour intervals are shown.

2.2.5

Siderophore preparations and plate bioassays

Concentrated culture supernatants enriched for staphyloferrin A (SA) and staphyloferrin
B (SB) were prepared from S. aureus Δsbn and Δsfa mutants, respectively, as previously
described (23). Concentrated culture supernatants from S. lugdunensis were similarly
prepared. In brief, strains were grown in C-TMS with aeration, for 40 hours. Bacterial
cells were removed by centrifugation and supernatants were lyophilized overnight and
resuspended in methanol (one-fifth the original culture volume). Insoluble material was
removed by centrifugation and the soluble fraction was rotary evaporated. Dried material
was resuspended in water (one-tenth the original culture volume). The ability of
concentrated culture supernatants to support staphylococcal growth was assessed using
the plate bioassay technique as previously described (35). To assess growth promotion on
S. lugdunensis cells, 1 x 104 cells mL-1 were incorporated into TMS-agar containing 5
µM EDDHA. Chloramphenicol was incorporated into media with strains harbouring
pRMC2, or vector derivatives. Staphyloferrin A and staphyloferrin B were also
synthesized enzymatically, using procedures that have been previously described (20,
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36). Siderophores/supernatants were applied to sterile paper disks and placed onto the
plates. Growth around disks was measured after 24 hours.

2.2.6

Chrome azurol S assay

Supernatants of iron-starved staphylococci were concentrated by lyophilization to 1/10 of
their original volume and tested for iron-binding compounds using the chrome azurol S
shuttle solution (37), as previously described (36).

2.2.7

Analysis of iron-regulated protein expression by Western
blotting

Antisera against S. aureus HtsA and SirA used in this study were generated previously
(23, 38). The antisera were used to assess the expression of homologous proteins in S.
lugdunensis, as described below.
For analysis of iron-regulated protein expression in whole-cell lysates, cells were
grown in C-TMS with or without 50 µM FeCl3 for 24 hours, normalized to an OD600 of 1,
and lysed. Proteins in lysates were resolved through SDS-polyacrylamide gel
electrophoresis using a 12% acrylamide resolving gel. For Western immunoblots,
proteins were transferred from gels to a 45-µm nitrocellulose membrane via standard
protocols (39). Detection of transferred proteins was performed after blocking the
membrane at 4oC for 12 hours in PBS containing 10% w/v skim milk and 20% v/v horse
serum. The membrane was washed and the primary antibody was applied at room
temperature for 2 hours (1:3,000 dilution) in PBS with 0.05% Tween 20, and 5% horse
serum. The membrane was washed again, and anti-rabbit IgG conjugated to IRDye 800
(Li-Cor Biosciences) was used as the secondary antibody, applied at room temperature
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for 1 hour (1:20,000 dilution), in the same buffer as the primary antibody. Fluorescence
was analyzed on a Li-Cor Odyssey infrared imager (Li-Cor Biosciences).

2.2.8

Staphylococcal growth in co-culture

Staphylococci were grown for 4 hours in C-TMS. Cells were washed three times in CTMS and normalized to an OD600 of 1 (S. lugdunensis) or 0.1 (S. aureus). Staphylococci
were inoculated into 2 mL of medium (80:20 C-TMS:horse serum) either in monoculture
or in co-culture. For co-cultures, equal volumes of washed cells from each species were
added. The 2-mL cultures were in 14-mL round-bottom polypropylene tubes and shaken
at 200 rpm. Samples were taken at time 0, 12, and 24 hours for dilution and plating on
TSA to obtain values for viable colony-forming units (CFUs). TSA plates were incubated
at 37oC for 24 hours and subsequently at room temperature for 2 days. Staphylococci
were distinguished based on colony colour and morphology; S. aureus colonies were
visibly larger in diameter and with lighter pigmentation, whereas S. lugdunensis colonies
were distinguishably smaller (approximately ¼ to ½ the diameter of S. aureus colonies)
and dark yellow under these culture conditions.

2.2.9

Preparation of hemin and hemoglobin

A solution of bovine hemin (Sigma Aldrich) was prepared as follows. A stock solution at
5 mM in 0.1 N NaOH is prepared and vigorous vortexing ensures the hemin is solubilized
completely. The solution is filtered through 0.2 micron filter. The final concentration of
hemin, post-filtration, was determined by making dilutions in 0.1 N NaOH and
measuring the UV-Vis spectra, using the molar extinction coefficient for hemin in 0.1 N
NaOH of 58400 cm-1 M-1 at 385 nm. Hemin stocks were stored at -20°C. For use in
growth assays, hemin stocks are diluted in growth media immediately prior to use.
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For hemoglobin purification, 25 mL of fresh, heparinized human blood was
centrifuged at 1500 × g at 4°C for 10 minutes to pellet the erythrocytes. Erythrocytes
were washed three times in three pellet volumes of ice-cold sterile saline and
subsequently lysed through resuspension in two pellet volumes of 50 mM Tris pH 8.6, 2
mM EDTA. Erythrocyte lysis was allowed to proceed for 30 minutes at room
temperature, mixing periodically by gentle inversion. Cell debris was removed by
centrifugation at 11000 × g for 30 minutes at 4°C. The supernatant was transferred to a
fresh tube and solid NaCl was added (50 mg/mL), with mixing by inversion. The stroma
was then precipitated by centrifugation at 11000 × g for 30 minutes at 4°C. The
hemoglobin-containing supernatant was dialyzed overnight at 4°C against 50 mM Tris
pH 8.6, 1 mM EDTA (Buffer A). The dialyzed hemoglobin was passed once through a
0.4 µM syringe filter prior to purification via anion exchange on a Mono Q HR 16/10
column (GE Healthcare). Dialyzed hemoglobin solution was loaded in 4-6 mL batches on
the column and a gradient run using 50 mM Tris pH 8.6, 1 mM EDTA, 0.5M NaCl as
Buffer B; hemoglobin fraction eluted between 50 – 100 mM NaCl. The purified fractions
were dialyzed into 50 mM Tris pH 8.0 and sterilized by passage through a 0.4 µM
syringe filter. Purity was assessed using UV-Vis spectrometry. Briefly, a spectral scan
was run between 200-800 nm, where a characteristic Soret peak at 415 nm, as well as
distinct α576 nm and β541 nm bands, and a peak at 345 nm, were indicative of intact ferrous
oxyhemoglobin. Hemoglobin concentration was determined using published extinction
coefficients at 560 and 577 nm (40) and was concentrated to 2 mM using Amicon Ultra15 centrifugation units (30 kDa NMWL, Millipore). Small aliquots were flash frozen in a
dry ice-ethanol bath and stored at -80°C.
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2.2.10

Assessment of hemin and hemoglobin utilization by S.
lugdunensis

In assessing hemin/hemoglobin utilization, single, isolated colonies of S. lugdunensis
from overnight TSA plates were resuspended in 120 µL RPMIC. 100 µL of this
suspension was used to inoculate 2 mL RPMIC with 0.1 µM EDDHA, which was grown
for at least 4 hours until OD600 was approximately 1. Precultures were subcultured 1:400
into 2 mL aliquots of RPMIC with 1 µM EDDHA and either 1-500 nM human
hemoglobin, purified as described above, 20-1000 nM hemin, prepared as described
above, or 1 µM FeSO4. Cultures were incubated with shaking at 200 rpm, in 14-mL
round-bottom polypropylene tubes. OD600 was assessed at 12, 24, and 36 hours.

2.3 Results
2.3.1

Sequence analysis of key iron acquisition loci in S.
lugdunensis

S. aureus contains several key iron acquisition loci that are well-characterized. These
include the isd locus that promotes iron acquisition from heme and hemoglobin, the sfahts locus for synthesis and re-entry of staphyloferrin A (SA), and the sbn-sir locus for
synthesis and uptake of staphyloferrin B (SB) (18, 19). The genome sequences of S.
lugdunensis strains N920143 and HKU01-09 indicate that these strains possess htsABC
genes downstream from an sfa locus (Figure 2-1A), with predicted products that are
highly similar to the S. aureus HtsABC proteins (Table 2-2). However, in contrast to S.
aureus, the S. lugdunensis sfa locus in both strains contains a deletion of approximately
3.3 kb that eliminates the sfaA and sfaD genes, as well as the promoter for the remaining
sfaBC genes (Figure 2-1A). This suggests that S. lugdunensis does not synthesize SA, yet
may be able to utilize it as an iron source, via HtsABC, if SA were provided
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Table 2-2: Similarity of iron-regulated proteins between S. aureus and S.
lugdunensis.
Protein

% ID / % TS

HtsA

70/82

HtsB

60/74

HtsC

71/87

SfaB

43/68

SfaC

57/79

SirA

85/92

SirB

84/94

SirC

74/84

IsdC

57/67

IsdE

75/85

IsdB

35/52

IsdA (Sa) vs IsdJ (Sl)

19/29

IsdA (Sa) vs IsdK (Sl)

14/31

Abbreviations: ID, identity; TS, total similarity; Sa, S. aureus; Sl, S. lugdunensis
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exogenously. In contrast to S. aureus, S. lugdunensis lacks the sbn operon, which encodes
the products responsible for synthesizing SB. Interestingly, S. lugdunensis possesses
homologs of the S. aureus sirABC genes (predicted products are highly similar to those
from S. aureus, see Table 2-2), which encode a SB transporter, and these genes are
situated immediately downstream of the S. lugdunensis isd locus (Figure 2-1B). In
comparison to S. lugdunensis N920143, strain HKU01-09 contains an exact, tandem
duplication of a large region of DNA encompassing the isd-sir locus (Figure 2-1B).
Together, the sequence analysis of these loci suggests that S. lugdunensis should not be
able to synthesize either SA or SB, in contrast to S. aureus, which synthesizes and
secretes both staphyloferrin molecules. On the other hand, we would predict that S.
lugdunensis should be able to transport iron via these siderophores, as well as acquire
iron from heme/hemoglobin via Isd proteins.

2.3.2

S. lugdunensis grows poorly in iron-restricted media, owing
to a lack of siderophore production

Our previous studies showed that, in comparison to wildtype S. aureus, mutants lacking
the ability to synthesize the two staphyloferrin siderophores (i.e. sfa sbn) grow poorly in
iron-restricted media containing transferrin or serum (as a source of transferrin) (23, 24).
Given that S. lugdunensis genomic information suggests an inability to produce a
staphyloferrin siderophore, we compared the growth of S. lugdunensis to that of S. aureus
and its staphyloferrin-deficient mutants in iron-restricted media. In comparison to
wildtype S. aureus, S. lugdunensis grew poorly in C-TMS with 20% serum (Figure 2-2A)
or transferrin (data not shown) and, even after extended incubation periods, never reached
a final biomass equivalent to that of S. aureus.
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Figure 2-2: Staphylococcus lugdunensis grows poorly in iron-restricted growth
media. (A) Growth kinetics comparing S. lugdunensis to that of Staphylococcus
aureus WT and staphyloferrin A (sfa) and staphyloferrin B (sbn)-deficient mutants in CTMS with 20% serum. (B) The growth deficiencies of S. lugdunensis and the S.
aureus staphyloferrin-deficient mutant in iron-restricted media are complemented with
addition of 100 µmol/L FeCl3. All data points represent average values for at least three
independent biological replicates, and error bars represent standard deviation from the
mean.
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Indeed, in these culture conditions, S. lugdunensis HKU01-09 (strain HKU01-09 was
used throughout this study) grew at a slower rate than the S. aureus sfa sbn mutant. We
demonstrated that the growth deficiency of S. lugdunensis and S. aureus sfa sbn was due
to a deficiency in the ability to scavenge trace amounts of iron, since supplementation of
the growth medium with 100 µM FeCl3 promoted rapid growth of both (Figure 2-2B).
In further support of the bioinformatics analyses indicating that S. lugdunensis is
incapable of staphyloferrin production, the culture supernatants of S. lugdunensis, grown
in C-TMS, tested negative in the chrome azurol S assay (Figure 2-3A), indicating a lack
of secreted iron-binding molecules. This is in contrast to the positive result obtained for
S. aureus culture supernatants grown in the same media and under the same conditions.
In support of the result that we could not detect iron-binding molecules in the
iron-restricted culture supernatant of S. lugdunensis, we demonstrated that concentrated
culture supernatants of S. lugdunensis were incapable of enhancing iron-restricted growth
of S. aureus (Figure 2-3B).

2.3.3

S. lugdunensis HtsABC and SirABC function as transporters
for staphyloferrins A and B, respectively

Despite not synthesizing staphyloferrin A, S. lugdunensis has htsABC homologs that, in
S. aureus, are required for utilization of ferric-SA complexes. Promoters containing
putative Fur box sequences are found upstream of the htsABC and sirABC operons in S.
lugdunensis (Figure 2-4A), suggesting that each operon is iron-regulated in a Furdependent fashion. Due to high amino acid sequence similarity of the S. lugdunensis
HtsA and SirA with the S. aureus homologs (see Table 2-2), antibodies raised against S.
aureus HtsA and SirA were used to successfully demonstrate iron-regulated expression
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Figure 2-3: Staphylococcus lugdunensis does not secrete iron-binding compounds,
and does not support Staphylococcus aureus growth in iron-restricted media. (A)
Chrome azurol S (CAS) assay demonstrates that culture supernatants of S.
lugdunensis lack siderophore activity. (B) Agar plate bioassays demonstrate that the
culture supernatant of S. lugdunensis does not promote the growth of iron-restricted S.
aureus strains. Ferric citrate was used as a positive control in the experiment. All data
points represent average values for at least three independent biological replicates, and
error bars represent standard deviation from the mean.
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of the S. lugdunensis proteins (Figure 2-4B). We next deleted the htsABC genes from the
S. lugdunensis genome and complemented the genes in trans by cloning the htsABC
genes from S. lugdunensis back into the mutant strain, which restored expression of HtsA
to the mutant strain (Figure 2-4B).
To generate a S. lugdunensis mutant lacking both copies of sirABC, we deleted
the entire tandemly-duplicated region (Figure 2-1B) from the genome, a deletion of
approximately 65-kbp. As expected, the mutant failed to express SirA (Figure 2-4B).
Complementation of this isd-sir deletion strain with the sirABC genes from S.
lugdunensis restored expression of SirA (Figure 2-4B).
With mutant and complemented strains in hand, we used them to test the ability of
the strains to utilize the two staphyloferrin siderophores produced by S. aureus. As
shown in Figure 2-5, the ability of S. lugdunensis strains to utilize SA and SB, whether
provided in concentrated culture supernatants from S. aureus, or as enzymaticallysynthesized molecules (data not shown), was absolutely dependent on the expression of
htsABC and sirABC, respectively. Moreover, while the growth of S. lugdunensis was
enhanced when the intact S. aureus sfa gene locus was introduced on a plasmid (Figure 23B), the same plasmid was incapable of complementing the iron-restricted growth defect
of the S. lugdunensis htsABC mutant (data not shown). Together, these data prove that
both the HtsABC and the SirABC transporters are functional in S. lugdunensis.
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Figure 2-4: Expression of Staphylococcus lugdunensis HtsA and SirA homologues is
iron-regulated. (A) Identification of Fur-boxes upstream of the htsA, sirA and
isdC genes in S. lugdunensis. Numbers represent the number of identical bases between
the 19-bp Fur boxes of S. aureus and S. lugdunensis. (B) Western blots demonstrating
iron-regulated expression of HtsA and SirA, and confirmation of mutations and
complementation, where pRMC2 is the vehicle control. Cultures were grown in C-TMS
with (+Fe) or without (−Fe) addition of FeCl3 (25 µmol/L). Mutant samples were all
grown in C-TMS without addition of iron.
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Figure 2-5: Plate bioassays demonstrate that Staphylococcus lugdunensis HtsABC
and SirABC are required for uptake of staphyloferrin A and staphyloferrin B,
respectively. Water and ferric citrate were used as negative and positive controls,
respectively. Supernatant extracts supplied were those of Staphylococcus aureus mutants
that secrete SA (sbn mutant), SB (sfa mutant) or neither SA or SB (sfa sbn mutant). All
data points represent average values for at least three independent biological replicates,
and error bars represent standard deviation from the mean.
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2.3.4

S. aureus enhances S. lugdunensis growth in a
staphyloferrin-dependent manner

As shown above, we demonstrated that exogenously added staphyloferrins could promote
the growth of S. lugdunensis. Knowing this, we next decided to test whether S. aureus,
which secretes both SA and SB, could augment the growth of S. lugdunensis if they were
cultured together in iron-restricted growth media. We first optimized culture conditions
so as to be able to easily discern colonies of S. aureus RN6390 from those of S.
lugdunensis HKU09-01 on TSA (Figure 2-6A) (see Experimental Procedures for details).
Figure 2-6B demonstrates that, when cultured in C-TMS containing 20% serum,
wildtype S. aureus consistently grows from 2 x 104 CFU/mL to approximately 1 x 109
CFU/mL within 24 hours, whereas the isogenic staphyloferrin-deficient mutant grows to
a density of only 1 x 107 CFU/mL over the same time frame. S. lugdunensis, on the other
hand, inoculated at a higher cell density of 1 x 106 CFU/mL, only reaches a final cell
density of less than 1 x 108 CFU/mL in 24 hours. The isogenic S. lugdunensis isd-sir hts
mutant displays identical growth kinetics in these culture conditions.
For co-culture experiments, in pilot studies, we found that we needed to inoculate
S. lugdunensis at much higher cell densities than S. aureus because S. aureus grows
significantly faster than S. lugdunensis in these culture conditions. Data displayed in
Figure 2-6C demonstrate that, when wildtype S. aureus is co-cultured with wildtype S.
lugdunensis, S. lugdunensis grew to much higher density, approximately 2 x 108, than
when cultured on its own (c.f. Figure 2-6B vs Figure 2-6C). We next demonstrated that
this growth enhancement was due to the use of the S. aureus-produced staphyloferrins by
S. lugdunensis by use of two complementary experiments (Figure 2-6C). First, wildtype
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Figure 2-6: Coculture experiments demonstrate that Staphylococcus aureusproduced siderophores can enhance the iron-restricted growth of Staphylococcus
lugdunensis. (A) Picture of colonies of S. aureus RN6390 (large and white) and S.
lugdunensis (smaller and yellow) growing on a TSB plate after 24 h of incubation at
37°C, followed by 48 h of incubation at room temperature. (B) Growth of individual
strains in C-TMS + 20% serum was monitored for CFU/mL at 12 and 24 h timepoints.
(C) Growth of strains in cocultures with the pairs of strains grouped as indicated. All data
points represent average values for at least three independent biological replicates, and
error bars represent standard deviation from the mean. The Student's unpaired t-test was
used to define statistical significance for the CFU values between strains as indicated by
the brackets. *P < 0.0001.
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S. aureus did not enhance the growth of the S. lugdunensis isd-sir hts mutant like it did
wildtype S. lugdunensis. Second, staphyloferrin-deficient S. aureus had no effect on the
growth of wildtype S. lugdunensis. Together, these data provide convincing evidence that
S. aureus, through production of SA and SB, enhances the iron-restricted growth of S.
lugdunensis in a HtsABC- and SirABC-dependent manner, respectively.

2.3.5

The S. lugdunensis isd-sir mutant is attenuated for utilization
of heme and hemoglobin

Having constructed a complete isd locus deletion strain of S. lugdunensis HKU01-09, we
next evaluated the mutant for its ability to utilize heme and hemoglobin as sole sources of
iron. Zapotoczna et al. (29) have also recently generated isdB and isd locus deletion
mutants in S. lugdunensis strain N920143 and shown that the mutants were impaired for
growth on hemoglobin compared to wildtype. These experiments were performed using a
single concentration of hemoglobin, and hemin as a sole iron source was not tested. We
took a more comprehensive approach by examining the growth of the isd-sir deletion
mutant in iron-starved media containing a range of hemin and hemoglobin
concentrations, in media that contained enough of the non-metabolizable iron chelator
EDDHA to completely restrict growth unless an iron source was added. Importantly,
when FeSO4 was provided as a source of free iron, S. lugdunensis and the isogenic isd-sir
mutant grew equally well (Figure 2-7A). It is notable that the isd-sir mutant is attenuated
for growth at all concentrations of hemoglobin tested (500 nM down to 10 nM; 1 nM
hemoglobin is insufficient to promote growth of wildtype under these conditions),
especially at 12 hours but also by the 24 hour timepoint (Figure 2-7B). By 36 hours it was
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Figure 2-7: Growth of Staphylococcus lugdunensis WT and its isogenic Δisd mutant
using iron, hemoglobin or heme as a sole iron source. Growth of the Δisd-sir mutant
was compared to that of WT strain HKU09-01 at 12-, 24- and 36-h timepoints in RPMIC
with 1 µM EDDHA, containing FeSO4 (A) varying concentrations of human hemoglobin,
(B) or varying concentrations of bovine hemin, (C) as the sole iron source. All data points
represent average values for at least three independent biological replicates, and error
bars represent standard deviation from the mean. Statistical significance was determined
using the Student's unpaired t-test; *P < 0.05; **P < 0.01; ***P < 0.0001.
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apparent that hemoglobin was beginning to promote the growth of the mutant, especially
at the higher hemoglobin concentrations. Notably, at the low nM concentrations of
hemoglobin (i.e. below 50 nM), the isd-sir mutant is significantly attenuated for growth,
compared to wildtype, even through 36 hours of incubation.
A similar growth pattern was observed for the isd-sir mutant when hemin was
used as the sole iron source (Figure 2-7C). It is apparent that the isd-sir locus provides a
significant growth advantage to S. lugdunensis at early stages of growth at all
concentrations tested (up to 1 µM) and continues to provide a significant growth
advantage to the cells through 36 hours of incubation in the presence of hemin at
concentrations below 100 nM (Figure 2-7C).

2.4 Discussion
S. lugdunensis is a relatively recently recognized bacterium that is both a commensal, and
an important human pathogen, capable of causing serious infections such as aggressive
native valve infective endocarditis (IE) (8). That IE caused by S. lugdunensis can occur
independent of indwelling medical devices differentiates S. lugdunensis from other
CoNS, and makes it worthy of investigation. Molecular studies of S. lugdunensis are in
their infancy and, thus, there is a paucity of information concerning important virulence
factors that underpin the potential of this opportunistic pathogen to cause severe and
invasive infections. The molecular mechanisms of iron acquisition that are key to the
biology and infectivity of this bacterium are essentially unknown. Zapotoczna et al. (29)
examined the role of the iron-regulated surface determinant system in the utilization of
hemoglobin and found that, in strain N920143, the Isd-dependent heme/hemoglobin
utilization system is functional by demonstrating that an isd deletion mutant and an isdB
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mutant were both slightly debilitated for growth on hemoglobin as a sole iron source.
Moreover, S. lugdunensis IsdG, like its S. aureus counterpart, degrades heme to
staphylobilin and free iron (26). In this study, we furthered these findings by
demonstrating that the tandemly-duplicated S. lugdunensis isd locus in strain HKU09-01
was required for promoting early and rapid growth on a wide range of hemoglobin and
heme concentrations ranging from 10-500 nM and 50-1000 nM, respectively (Figure 27B and 2-7C), eventually leading to increased bacterial biomass that was sustained
through 36 hours of incubation, especially at the lower concentrations. It is worth noting
that these low concentrations of hemoglobin and heme are physiologically relevant, since
these molecules are removed from circulation in the liver subsequent to being quickly
bound by haptoglobin and hemopexin, respectively.
S. lugdunensis is severely attenuated for growth in iron-restricted media that do
not contain a readily utilizable iron source such as hemin or hemoglobin. In media
containing serum or transferrin, for example, S. lugdunensis is severely compromised for
growth compared to S. aureus. We have shown that this growth defect is readily
corrected with excess iron, indicating an inability to attain iron from the media. Based
upon previous studies, it is known that the sfa gene cluster from S. aureus is both
necessary, based on the phenotype of sfa mutants (23) and sufficient, based on
heterologous cloning in E. coli (41) for staphyloferrin A synthesis. S. lugdunensis
supernatant lacks siderophore activity (Figure 2-3A) and does not support iron-restricted
S. aureus growth (Figure 2-3B), indicating a lack of staphyloferrins A and B.
That the sfa deletion is found in both S. lugdunensis strains where genome
sequence is available suggests that this deletion may be common to the species. The
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deletion (see Figure 2-1A) removes the promoter for each of the two transcripts sfaD and
sfaABC, and also completely removes the sfaA and sfaD genes, encoding the putative SA
efflux pump (SfaA) and one of the synthetases that joins a citrate molecule to the δ-amine
of D-ornithine to form the first amide intermediate of staphyloferrin A (41). Studies in
the early 1990s identified staphyloferrin A in culture supernatants of many species of
staphylococci, whereas staphyloferrin B was found in supernatants of fewer species (42,
43). Of the species tested, which did not include a S. lugdunensis representative, only S.
sciuri and S. hominis were found incapable of producing either siderophore, but only one
strain was tested from each of these species and the result may not reflect the capabilities
of the species overall. Based on available genomic data, on the other hand, S. lugdunensis
(genome data exist for strains N920143 and HKU09-01) appears to be unique amongst
the staphylococci in its inability to synthesize at least one of the two staphyloferrin
molecules. This would imply that, if other S. lugdunensis strains also lack these loci, the
species causes opportunistic infections independent of siderophore production, and would
presumably rely on either heme acquisition or uptake of xenosiderophores to satisfy its
iron requirements throughout the various stages of colonization and infection. Genomic
information identifies that S. lugdunensis has homologs of fhuCBG and sstABCD where
predicted products share high levels of similarity with those in S. aureus (24, 35). This
would indicate that S. lugdunensis is capable of using hydroxamates (via FhuCBG) and
catechols/catecholamines as means to acquire iron. The S. lugdunensis FhuC ATPase
shares greater than 95% similarity with its S. aureus counterpart and we hypothesize that
this ATPase is, like in S. aureus (44), important for providing the energy for not only the
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uptake of hydroxamate siderophores, but also the staphyloferrins through HtsABC and
SirABC.
Interestingly, despite its noted ability to cause serious infection in humans, S.
lugdunensis N920143 was reported to cause only very mild infection in a rat model of
endocarditis, much milder than that which would be caused by equivalent CFUs of S.
aureus (25). In pilot experiments we, too, noted a relative lack of virulence of S.
lugdunensis HKU09-01, using a mouse model of hematogenous spread. Mice challenged
with up to of 1 × 108 CFUs showed no overt signs of illness, and continued to gain
weight, despite detectable counts in the kidneys for at least 7 days following bacterial
challenge via tail vein. This contrasts from the course of disease that would be caused by
a much lower dose of S. aureus. As noted previously (8, 25, 27, 28), the S. lugdunensis
genome indicates an absence of orthologues of well-characterized S. aureus toxin and
immune evasion encoding genes, suggestive of a limited capacity to cause severe disease,
at least in comparison to S. aureus.
That S. lugdunensis has retained the transport machinery for both staphyloferrin A
and staphyloferrin B is interesting, despite an inability to synthesize either siderophore.
This may represent a mechanism for scavenging these iron-binding molecules produced
by other species of staphylococci, including S. aureus. Indeed, our data show that coculture of the two bacteria in the same iron-limited growth media enhanced the growth of
S. lugdunensis by at least one log. This growth enhancement was due to S. lugdunensis'
ability to scavenge the S. aureus staphyloferrins in an Hts- and Sir-dependent manner.
We speculate that this is a viable 'opportunistic' strategy used by S. lugdunensis in vivo.
Although S. lugdunensis predominantly inhabits lower parts of the human body (i.e. the
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perineum) (9) and S. aureus largely inhabits the nares, both species are present to some
degree over the entire external surface of the body (45–47). Indeed, S. lugdunensis is
recovered with other bacteria in approximately 60% of infections, including cooccurrence with S. aureus and other staphylococci (7). It may be that over time S.
lugdunensis has evolved to simply steal siderophores produced by other species of
bacteria, including S. aureus, and in these situations is more capable of causing
opportunistic infections of humans.
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Chapter 3
Ferric hydroxamate and stress hormone acquisition by
Staphylococcus lugdunensis
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3.1 Introduction
Iron is an essential nutrient for nearly all forms of life as it is required for cellular
processes including amino acid, DNA synthesis and respiration. In aerobic conditions,
ferric iron (FeIII) is insoluble at neutral pH and the concentration of free iron is well
below the requirement to support microbial growth (1). Ferrous iron (FeII) is able to
catalyze the formation of free radicals which elicit macromolecular damage on cells (2).
Iron within mammals is sequestered in order to alleviate toxicity and purpose it for
cellular processes. The majority of iron within the host is bound within heme in
hemoglobin, predominantly found within circulating erythrocytes (3). Alternatively, iron
may be bound within the intracellular iron-storage protein ferritin, or sequestered by
extracellular glycoproteins such as transferrin and lactoferrin (1, 4). Transferrin has a
high binding affinity for ferric iron (KD of approximately 10-22 M) and is the primary
iron-sequestration factor in vertebrate serum (5). As such, the circulating concentration of
free iron is well below the requirement to support invading pathogen growth, and iron
sequestration by the host remains an important form of nutritional immunity (1).
Staphylococcus lugdunensis, like several other coagulase-negative staphylococci
(CoNS), is a human skin commensal. However, it is also regarded as an emerging
pathogen with elevated virulence compared to other species of CoNS. Infections are
reminiscent of those caused by S. aureus and when host external protective barriers are
breached, S. lugdunensis is able to cause an array of distinct infections including skin and
soft tissue infections (SSTIs), bacteremia, pneumonia, and osteomyelitis (6–9). Although
most commonly associated with SSTIs, S. lugdunensis is best known for causing
aggressive infective endocarditis, which can bear a mortality rate of up to 50% (10, 11).
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Additionally, many reports detail S. lugdunensis endocarditis following skin trauma or
surgical procedures including vasectomy and kidney transplant (9, 12–14). The versatility
of this pathogen to colonize different host niches likely requires S. lugdunensis to adapt
its cellular physiology to overcome challenges presented in these diverse environments,
including iron limitation. As such, the ability to acquire host iron as an essential nutrient
must contribute to growth promotion of S. lugdunensis in various host niches.
Many pathogens overcome host iron limitation through the ability to acquire
heme from hemoglobin (15, 16). The iron-regulated surface determinant (Isd) system was
first identified in S. aureus and acts as a multiprotein transport pathway to exploit host
hemoglobin to acquire heme-iron (17, 18). The Isd pathway is able to extract heme from
hemoglobin at the bacterial cell surface and transport it across the cell wall and through
the cytoplasmic membrane into the cytoplasm, using a consort of proteins (19–22).
Function of the Isd system in S. aureus is critical to its pathogenesis, and S. lugdunensis
is unique among CoNS to encode a similar pathway (23–26). The S. lugdunensis Isd
system is not nearly as well characterized, however studies have shown that it does
function to acquire heme and hemoglobin-iron at nanomolar concentrations, for growth
under iron-limitation (27–29).
Another strategy of iron acquisition is the removal of iron from glycoproteins,
such as transferrin, via secreted siderophores (low molecular weight, high affinity FeIII
chelators) (30). S. aureus elaborates the siderophores staphyloferrin A (SA) and
staphyloferrin B (SB), of which biosynthetic proteins are encoded by sfa and sbn loci,
respectively (31, 32). SA is transported into the cell by HtsABC and SB is transported
through SirABC, each of which are encoded by loci adjacent to their respective cognate
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siderophore biosynthetic genes (33, 34). Although both SA and SB are required for
optimal growth of S. aureus in human serum, SB is thought to be the more predominant
of the two during systemic infection, whereas SA has been found to contribute to the
formation of subcutaneous lesions in S. aureus-infected mice (16, 35). Contrary to other
staphylococci, S. lugdunensis is unable to produce either SA or SB, due to gene deletions,
contributing to its inability to grow in animal serum, although it has retained the transport
pathways for both of these siderophores (28).
In addition to SA and SB, S. aureus can also capture xenosiderophores bearing
hydroxamate moieties through the use of the ferric hydroxamate uptake (Fhu) pathway
(31, 36, 37). Furthermore, the iron-withholding capability of serum may be compromised
by host-produced stress hormones (catecholamines), which are able to reduce FeIII
within transferrin to FeII, thereby releasing it (38–42). Catecholamine stress hormones
are able to form 2:1 or 3:1 complexes with FeIII and may provide iron as a
‘pseudosiderophore’ to bacteria expressing catechol transport systems. It has been shown
that S. aureus employs the Sst transporter to acquire catecholamine-iron for growth in
low-iron environments (41). There exists a paucity of information regarding the
mechanisms of iron acquisition in S. lugdunensis and their role in virulence.
In this study we investigate iron procurement strategies of S. lugdunensis by
characterizing siderophore and host stress hormone acquisition strategies. We
demonstrate that fhuC is required for acquisition of hydroxamate and polycarboxylate
(SA and SB) siderophores. Furthermore, we examine the role of the inexact-duplicated
Sst gene sets in S. lugdunensis, finding differences in ligand-binding affinity and
expression pattern between the two. Additionally, we utilize a novel S. lugdunensis
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systemic murine infection model to demonstrate that a isd fhuC sst mutant is impaired for
growth in kidneys, and for inducing weight loss.

3.2 Experimental procedures
3.2.1

Bacterial strains and media

Bacterial strains and vectors employed in this study are summarized in Table 3-1.
Escherichia coli strains were grown in Luria-Bertani broth (LB, BD Diagnostics) or on
LB agar. For routine culture and genetic manipulation, S. lugdunensis and S. aureus
strains were cultured in tryptic soy broth/agar (TSB/TSA; BD Diagnostics) or on TSB
agar. For growth experiments, S. lugdunensis and S. aureus were cultured in: (i) RPMI
1640 (Life Technologies) supplemented with 1% w/v casamino acids (BD Diagnostics)
(RPMIC) and ethylenediamine-di(o-hydroxyphenylacetic acid) (EDDHA; LGC
Standards GmbH); (ii) Tris-minimal succinate (TMS) broth/agar (43); (iii) TMS treated
with 5% (w/v) Chelex-100 resin (Bio-Rad) at 4°C for 24 hours (C-TMS); or (iv) an 80:20
mixture of C-TMS and complement-inactivated horse serum (Sigma Aldrich). Bacteria
were cultured at 37°C with shaking at 220 rpm unless otherwise indicated. For E. coli
selection, 100 µg mL-1 ampicillin or 30 µg mL-1 kanamycin were used. For S.
lugdunensis and S. aureus selection, 10 µg mL-1 chloramphenicol was used.

3.2.2

Real-time PCR

Quantitative real-time PCR was performed as previously described (35). Briefly, S.
lugdunensis HKU09-01 RNA was prepared from triplicate 3 mL cultures grown in CTMS or C-TMS with 100 µM FeCl3. Cultures were harvested to an OD600 of 3.0 and
RNA was extracted using the Aurum Total RNA Mini Kit (BioRad). 500 ng extracted
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Table 3-1: Bacterial strains, plasmids and oligonucleotides used in this study.
Bacterial strain,

Descriptiona

Source or

plasmid or

reference

oligonucleotide
Strains
E. coli
DH5α

Φf80dlacZΔM15 recA1 endA1 gyrAB thi-1
−

Promega

−

hsdR17(rK mK ) supE44 relA1 deoR Δ(lacZYAargF)U169
BL21λ(DE3)

F−ompThsdSB(rB− mB−) dcmgal λ(DE3)

Novagen

H3320

BL21λ(DE3) pET28::sst1D; KmR

This study

H3321

BL21λ(DE3) pET28::sst2D; KmR

This study

HKU09-01

Human skin infection isolate

(25)

H2710

HKU09-01 Δisd-sir

(28)

H2970

HKU09-01 ΔfhuC

This study

H3016

HKU09-01 Δsst

This study

H3325

HKU09-01 Δisd-sir ΔfhuC Δsst

This study

S. lugdunensis

149

H3316

HKU09-01 ΔfhuC pRMC empty vector control;

This study

CmR
H3317

HKU09-01 ΔfhuC pRMC::fhuC (pfhuC); CmR

This study

Prophage-cured laboratory strain; rK− mK+;

(44)

S. aureus
RN4220

accepts foreign DNA
H1666

Newman ΔsbnABCDEFGHI::Tc
R

(41)

R

ΔsfaABCsfaD::Km; Tc Km
H2224

Newman ΔsstABCD::Em

(41)

ΔsbnABCDEFGHI::Tc ΔsfaABCsfaD::Km;
EmR TcR KmR
H3311

H1666 pRMC empty vector control; TcR KmR

This study

R

Cm
H3312

H2224 pRMC empty vector control; EmR TcR

This study

KmR CmR
H3313

H2224 pRMC::sst1; sst mutant complemented

This study

with S.lugdunensis sst1ABCD; EmR TcR KmR
CmR
H3314

H2224 pRMC::sst2; sst mutant complemented
with S.lugdunensis sst2ABCD; EmR TcR KmR
CmR

This study
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Plasmids
pKOR1

E. coli/Staphylococcus shuttle vector allowing

(45)

allelic replacement in staphylococci; ApR CmR
pKOR1ΔfhuC

pKOR1 plasmid for in-frame deletion of fhuC;

This study

ApR CmR
pKOR1Δsst

pKOR1 plasmid for deletion of genetic region

This study

encompassing duplicated sstABCD; ApR CmR
pRMC2

E. coli/Staphylococcus shuttle vector: ApR CmR

(46)

pRMC2::fhuC

pRMC2 derivative for fhuC expression; ApR

This study

R

Cm
pRMC2::sst1

pRMC2 derivative for sst1ABCD expression;
R

This study

R

Ap Cm
pRMC2::sst2

pRMC2 derivative for sst2ABCD expression;

This study

ApR CmR
pET28a(+)

E. coli vector for overexpression of recombinant Novagen
hexahistidine-tagged proteins; KmR

pET28::sst1D

pET28a(+) derivative encoding N-terminally
hexahistidine-tagged soluble portion of Sst1D;
KmR

This study
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pET28::sst2D

pET28a(+) derivative encoding N-terminally

This study

hexahistidine-tagged soluble portion of Sst2D;
KmR
Oligonucleotidesb,c
Purpose

Sequence (5'-3')

Primers for generating (AttB1)-fhuCUF:GGGGACAAGTTTGTACAAAAAAGCAGGCT
upstream and
downstream
recombinant regions
for ΔfhuC using

CTTGGTATTGGGATAATCG
fhuCUR: GTTGTCCATTCAAGCGAC
fhuCDF:Phos/CAGGCAAACCATTATTAGTTACC

pKOR1
(AttB2)fhuCDR:GGGGACCACTTTGTACAAGAAAGCTGGGT
TGTCAATGGCAATACTTTAG
Primers for generating (AttB1)-sstUF:GGGGACAAGTTTGTACAAAAAAGCAGGCT
upstream and
downstream
recombinant regions
for Δsst using pKOR1

TATTGCTCGGGTATCAAG
sstUR: GCCAACAAACAATGAAATG
sstDF: Phos/AAATCATCAGCCAAACAGG
(AttB2)-sstDR:GGGGACCACTTTGTACAAGAAAGCTGGGT
AAACACGCTGGCTTTATG

Primers for cloning

KpnI-fhuCF:

fhuC into pRMC2 for

GATCGGTACCAAGACGCAAGTGTCAAGAG

complementation

SacI-fhuCR:
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GATCGAGCTCACAGCACCTAAATCTCTTGG

Primers for cloning
sst1 into pRMC2 for
complementation
Primers for cloning
sst2 into pRMC2 for
complementation

KpnI-sst1F: GATCGGTACCTGCCTTAGACACAACGAC
SacI-sst1R: GATCGAGCTCGACTCGTAAGAAAGCAAACC

EcoRI-sst2F: GATCGAATTCAGGTTCTGTTGTTGGTGG
EcoRI-sst2R: GATCGAATTCTAAATGTTGTCCCGCTCC

Primers for cloning

NdeI-sst1DF:

sst1D into pET28a(+)

GATCCATATGGAAACAAAGAGTGGCGAATCA

for overexpression

SacI-sst1DR:
GATCGAGCTCGGAATGATATCCCCACTTCA

Primers for cloning

NdeI-sst2DF:

sst2D into pET28a(+)

GATCCATATGAGCTCAGATGCTAAGTCATCA

for overexpression

SacI-sst2DR:
GATCGAGCTCGCTAAACAAGATGTCTTGAAAT

Primers for RT-PCR
of rpoB

Primers for RT-PCR
of fhuC

Primers for RT-PCR

F: AGAGAAAGACGGCACTGAAAACAC
R: ATAACGACCCACGCTTGCTAAG
F: TGGACCAAATGGATGTGG
R: GCTACTTCTGGAGATTGTGG
F: CTCGTTTGCTTTCCTCAAG
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of sst1A

Primers for RT-PCR
of sst2A

Primers to confirm
deletion of sfaDA

Primers to confirm
presence of isdJK

Primers to confirm
presence of sirABC

Primers to confirm
duplicated sstABCD

a

R: TGCCACCCAACATAATACC
F: GGCATTATGTTAGGTGGTATTG
R: CGTCCACTTGTAATAATGGC
F: TGATAGTTTCTCTAATGCGTTCTC
R: CAGAATACATCAAATCTTGCG
F: GAATGATTTCCACCAGTCAG
R: GTTTCCCTTGAATCGTGAC
F: TACTGCTCCAAAATCCCC
R: TTTAGCGTGCGGTATGTC
F: GAGTTATCAACATTCGGC
R: AAGGGTCACTAACACATAG

ApR, CmR, KmR, EmR and TcR; resistance to ampicillin, chloramphenicol, kanamycin,

erythromycin and tetracycline, respectively.
b
c

Restriction sites for cloning are underlined.
Phos/ denotes a 5' phosphate on the primer.
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RNA was reverse-transcribed and PCR-amplified using iScriptTM One-Step RT-PCR Kit
with SYBR Green (Bio-Rad) and primers outlined in Table 3-1. Data were normalized
relative to expression of the rpoB housekeeping gene.

3.2.3

Blood cultures

The growth of several S. lugdunensis strains was assessed in iron-restricted media with
blood as a sole iron source. Single, isolated colonies were resuspended in 2 mL RPMIC
with 0.1 µM EDDHA and incubated for at least 4 hours until OD600 was about 2. Cultures
were normalized to an OD600 of 1 and 5 µL was subcultured into 2 mL culture medium
for a starting bacterial density of 2-5 x 106 CFU/mL. Culture medium consisted of 2 mL
RPMIC with 1 µM EDDHA and 0.001% fresh, whole human blood from healthy
volunteer donors, with or without addition of 50 µM FeCl3. Cultures were grown at 37°C
on a rotisserie for 20 hours prior to dilution and spot plating on TSA for bacterial
enumeration.

3.2.4

Molecular genetic methods

For in-frame deletion of fhuC and deletion of the tandem-duplicated sstABCD regions
(Δsst) in S. lugdunensis, allelic replacement using the pKOR1 vector was performed as
described previously (45). Briefly, 500 – 1,000-bp DNA fragments flanking regions of
interest were amplified using the primers found in Table 3-1. Upstream and downstream
flanking amplicons were cloned into pKOR1. Knockout vectors were passaged through S.
aureus RN4220 before introduction into S. lugdunensis by electroporation of 4µg DNA
(47, 48). Plasmids were integrated onto the genome at 43°C in the presence of
chloramphenicol prior to counter-selection at 30°C in the presence of anhydrotetracycline
(200 ng mL-1). Chloramphenicol-sensitive colonies were chosen for screening by PCR
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across the deleted region in the chromosome, which was further confirmed by sequencing
(45). The same process was used over to generate multiple deletions in one strain.
For complementation, S. lugdunensis fhuC, sstA1B1C1D1 and sstA2B2C2D2
were cloned with each respective native promoter, using primers described in Table 3-1.
Amplicons were cloned into pRMC2 for creation of pfhuC, psst1 and psst2, further
electroporated into target strains. For sstA2B2C2D2 cloning into pRMC2, alkaline
phosphatase treatment (Antarctic phosphatase; New England BioLabs) was performed
post-digestion to prevent self-ligation of the insert (both ends bear EcoRI cut sites).

3.2.5

Siderophore preparation and plate bioassays

S. aureus concentrated culture supernatants were prepared from Δsbn, Δsfa, and
ΔsbnΔsfa mutants, respectively, as described previously (31). Strains were grown in CTMS with aeration for 36 hours prior to removal of cells. Supernatants were lyophilized
and insoluble matter was removed by methanol extraction (one-fifth original culture
volume). Methanol was removed by rotary evaporation, and dried material was
resuspended in water to one-tenth culture volume to provide culture extracts.
Staphyloferrin B was prepared in-vitro enzymatically, as described previously (32, 34,
49). Enzymes were removed from the reaction mixture using an Amicon Ultra-0.5 10k
filter column (Millipore) and the Staphyloferrin B reaction mixture was normalized to
Deferoxamine (DFO, London Health Sciences Center) equivalents as determined using
the chrome azurol S (CAS) siderophore detection assay (50). Staphyloferrin A was
commercially prepared by Indus BioSciences (India). Ferric –enterobactin, -salmochelin
S4, -aerobactin and coprogen were purchased from EMC Microcollections. Ferrichrome
was purchased from Sigma, whereas citrate was purchased from Fisher Scientific.
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The ability of culture supernatants and purified siderophores to support S.
lugdunensis iron-restricted growth was assessed with agar plates using plate-based disk
diffusion bioassays (28, 51). Briefly, 1 x 104 S. lugdunensis cells were incorporated into
TMS-agar containing 5 µM ethylenediamine-di(o-hydroxyphenylacetic acid) (EDDHA,
LGC Standards GmbH). Siderophores/supernatants applied to sterile paper disks were
placed onto the agar, and growth around disks was measured after 24 hours at 37°C.

3.2.6

Iron-regulated protein expression by S. lugdunensis

Antisera against S. aureus SstD, used in this study, was previously prepared (41). This
antisera was used for analysis of iron-regulated SstD expression in S. lugdunensis. Cells
were grown in C-TMS with or without 100µM FeCl3 for 24 hours, normalized and lysed
with lysostaphin (Sigma). Whole cell lysates were normalized to 8 µg total protein and
resolved by SDS-polyacrylamide gel electrophoresis. Western blotting was performed as
previously described (28). The membrane was blocked in phosphate buffered saline
(PBS) with 10% (w/v) skim milk, 0.05% Tween 20 and 20% (v/v) horse serum.
Antiserum was applied at a 1:5,000 dilution in PBS with 0.05% Tween 20 and 5% horse
serum, prior to addition of anti-rabbit IgG conjugated to IRDye-800 (1:20,000 dilution;
Li-Cor Biosciences). The membrane was washed between each step. Fluorescence
imaging was performed using a Li-Cor Odyssey infrared imager (Li-Cor Biosciences).

3.2.7

Growth curves

Growth of S. lugdunensis and S. aureus strains was assessed in C-TMS with serum.
Single, isolated colonies were resuspended in 2 mL C-TMS and grown for over 4 hours
until OD600 was above 1. Each culture was normalized to an OD600 of 1 and subcultured
1:200 in C-TMS:horse serum. Wildtype S. lugdunensis as well as S. aureus strains
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bearing Δsbn and Δsfa mutations, are impaired for growth in this media compared to
siderophore-producing strains (28, 31). Human stress hormones were added to the media
for a final concentration of 50 µM to assess for catecholamine-iron acquisition for growth
enhancement. Dopamine hydrochloride, L-3,4-dihydroxyphenylalanine (L-DOPA), DLnorepinephrine hydrochloride, (-)-epinephrine, 2,3-dihydroxybenzoic acid (DHBA) and
2,5-DHBA were purchased from Sigma. Chloramphenicol was also included for strains
harbouring pRMC2 or derivatives. Cultures were grown in a Bioscreen C plate reader
(Growth Curves USA) at 37°C with constant shaking at medium amplitude. OD600 was
assessed at 15 minute intervals however, for graphical clarity, 4 hour intervals are shown.

3.2.8

Protein overexpression and purification

Recombinant S. aureus SstD was purified as previously described (41). Regions of the
genes encoding the soluble portions of S. lugdunensis SstD1 and SstD2 (excluding
lipobox motifs) were amplified and cloned into pET28(a)+ (Novagen) using primers
listed in Table 3-1. E. coli BL21 bearing pET28::sstD1 or pET28::sstD2 were grown to
mid-log phase at 37°C in LB with kanamycin, prior to induction with 0.4 mM isopropylβ-D-1-thiogalactopyranoside (IPTG). After addition of IPTG, cultures were grown at
25°C overnight. Cells were collected by centrifugation, resuspended in 20 mM Tris, pH
8.0, 500 mM NaCl, 10 mM imidazole (binding buffer), and ruptured in a cell disruptor
(Constant Systems Ltd). Insoluble matter and debris were removed by centrifugation at
3,000 x g for 15 minutes, followed by 150,000 x g for 60 minutes, sonicating samples in
between. Soluble material was filtered and applied to a nickel-loaded 1 mL HisTrap
column (GE Healthcare) equilibrated with binding buffer. His6-tagged proteins were
eluted in 1 mL fractions from the column over a 0-80% gradient of 20 mM Tris, pH 8.0,
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500 mM NaCl, 500 mM imidazole (elution buffer). Fractions bearing pure SstD1 and
SstD2 (analyzed via SDS-PAGE) were pooled and dialyzed into 10 mM Tris, pH 8.0, 100
mM NaCl (working buffer) at 4°C. Protein concentrations (Bio-Rad protein assay) were
normalized to equality and aliquots were frozen at −80°C.

3.2.9

Protein-ligand binding

Intrinsic tryptophan fluorescence quenching was used to assess protein-ligand binding
affinity for S. lugdunensis SstD1, SstD2 and S. aureus SstD as previously described (41).
Proteins were adjusted to 0.5 µM in 3 mL working buffer and ligands were added at 2fold concentration increments. Dopamine, L-DOPA, epinephrine, norepinephrine, DFO
and salmochelin S4 were used as ligands. Ligands were incubated in 3:1 (catecholamine
hormones) or 1:1 (siderophores) molar ratios to FeCl3 for 5 minutes at room temperature
prior to use. Bovine serum albumin (Sigma) was used as a protein negative control.
Fluorescence was measured at room temperature in a Fluorolog instrument (Horiba
Group), with excitation at 280 nm and emission detection at 345 nm. An excitation slit
width of 5 nm and an emission slit width of 5 nm were used. Changes in fluorescence due
to ligand additions and sample volume increase were corrected for (52). Fluorescence
intensity data analysis and KD determination were performed as previously described
(41).

3.2.10

Western blots

Recombinant proteins were analyzed for purity and immunogenicity towards αSstD (S.
aureus) antisera. S. lugdunensis SstD1, SstD2 and S. aureus SstD purified protein
volumes were normalized to contain 3 µg total protein and resolved by SDS-PAGE.
Western blotting was performed as described above (iron-regulated protein expression by

159

S. lugdunensis) with modifications. After blocking, αSstD antisera were applied at a
1:20,000 dilution, and αHis antibody was applied 1:10,000. Anti-rabbit IgG conjugated to
IRDye-800 (1:20,000 dilution) was secondary to αSstD antisera, whereas anti-mouse
Alexa Fluor 680 (Life Technologies) was secondary to αHis (1:20,000 dilution).
Antibodies/antisera were applied in PBS with 0.05% Tween 20 and 5% horse serum,
washing in between applications.

3.2.11

Spot dilution plate assays

Overnight TSB cultures of S. lugdunensis strains were pelleted, resuspended in saline and
normalized to an OD600 of 1.1. Normalized bacterial suspensions were ten-fold serially
diluted and 10 µL aliquots of 10-4 to 10-7 dilutions were spot plated onto TSA and TMS
agar. Images of TSB plates were taken after 17, 24 and 28 hours of incubation, whereas
images of TMS plates were taken after 24, 28 and 42 hours of incubation.

3.2.12

Murine model of systemic S. lugdunensis infection

All protocols for murine infection were reviewed and approved by the University of
Western Ontario’s Animal Use Subcommittee, a subcommittee of the University Council
on Animal Care. Six-week-old, female, BALB/c mice were obtained from Charles River
Laboratories and housed in microisolator cages. S. lugdunensis strains were grown to
mid-exponential phase (OD600 2 - 2.5) in TSB, washed twice with PBS, and resuspended
in PBS to an OD600 of 0.50. 100 µL of bacterial suspension, equivalent to 2-3 x 107 CFU,
was injected into each mouse via tail-vein. Mice were weighed at time of challenge and
every 24 hours after, where infection was allowed to proceed for 3-6 days before mice
were euthanized via intraperitoneal injection of pentobarbital. Organs were aseptically
harvested into PBS with 0.1% (v/v) Triton X-100, homogenized, diluted and plated onto
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TSA to enumerate bacterial burden. Weight data are presented as the difference in
percentage from mouse weight at time of challenge. Recovered bacterial load from
kidneys is presented as log10 CFU per kidney pair.

3.3 Results
3.3.1

Bioinformatic analysis of sequences implicated for iron
acquisition by S. lugdunensis

There are several known loci important for S. aureus iron acquisition. Isd proteins
acquire heme-iron from hemoglobin, sfa-hts and sbn-sir loci are required for biosynthesis
and transport of SA and SB, respectively, the fhu locus for hydroxamate siderophore
acquisition, and the sst locus for catecholamine uptake (41, 53, 54). The study of iron
acquisition mechanisms in S. lugdunensis, on the other hand, is still in its infancy. Several
genomic regions of interest were identified in S. lugdunensis based on sequence
comparison. Genome sequences of strains N920143 and HKU09-01 indicate a deletion in
the sfa locus such that sfaAD and the promoter region for sfaBC have been removed
(Figure 3-1A), yet downstream hts genes are intact and have been determined to be
functional for SA acquisition (28). No genes for SB synthesis are present in the S.
lugdunensis genome, and the bacterium is indeed inhibited for growth in serum compared
to S. aureus strains competent for either SA or SB production (28). Genes for SB
acquisition are proximal to genes for heme acquisition in the S. lugdunensis genome, and
the isd-sir region is in exact tandem duplication in strain HKU09-01 (Figure 3-1B). sir
and isd genes are required for SB acquisition and high-affinity heme acquisition from
hemoglobin, respectively, for this species (27, 28). S. lugdunensis possesses genes
homologous to S. aureus fhuCBG required for ferric-hydroxamate acquisition
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Figure 3-1: Physical maps of genetic loci implicated in Staphylococcus lugdunensis
iron transport. (A) Comparison of the S. aureus staphyloferrin A (SA) biosynthetic and
transport locus with the homologous gene set in S. lugdunensis. All sequenced S.
lugdunensis strains carry the depicted deletion, between the dashed lines, of sfaAD and
the promoter region for the remaining two biosynthetic genes. (B) The isd-sir locus in S.
lugdunensis is depicted. The region between dashed lines is duplicated in tandem in strain
HKU09-01, with an identical region upstream of sir genes (ATP-A duplicate at
SLGD_00087). (C) Ferric-hydroxamate transport locus in S. lugdunensis. (D) Ferriccatecholamine uptake loci in S. lugdunensis. The tandemly duplicated loci encode
proteins that share ~70% identity. Abbreviations as follows: Asp23; Alkaline shock
protein 23, ATP-A,B,C; K+-ATPase components A, B, and C, respectively, mem;
membrane protein, ABC; ATP-binding cassette transporter component, FMN; FMN
binding protein, NAT; N-acetyltransferase, marR; MarR-type regulator, hyp; hypothetical
protein, red; reductase, Pase; phosphatase, PT; phosphotransferase.
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(Figure 3-1C, Table 3-2). The S. aureus fhuC ATPase is somewhat promiscuous as it is
able to provide energy for transport of not only hydroxamates but also carboxylate
siderophores SA and SB (31, 36, 37). The functionality and promiscuity of FhuC in S.
lugdunensis is not yet known. Additionally, S. lugdunensis has gene sets homologous to
S. aureus sst (Figure 3-1D). Interestingly, the sst gene sets are tandemly duplicated but
are not identical at the sequence level (Table 3-2). All sequenced S. lugdunensis strains
have these tandemly duplicated sst gene sets, which we predict to transport ferriccatechols and catecholamines. Together, based on genome sequence data, we predict that
S. lugdunensis should be able to transport hydroxamate siderophores through the Fhu
transporter, and catecholamines through Sst1 and Sst2 transporters.

3.3.2

Prevalence of iron acquisition genes in S. lugdunensis
clinical isolates

Based on the genome sequences of strains HKU09-01 and N920143, S. lugdunensis
appears to harbor several key iron acquisition loci. To assess whether these strains are
indeed representative of all or the majority of clinical isolates, we PCR amplified iron
acquisition loci in a number of S. lugdunensis clinical isolates obtained from London
Health Sciences Centre - Victoria Hospital (London, Ontario, Canada) (see Table 3-1 for
primers used). Including prototype HKU09-01 strain, all isolates (27/27) have a deletion
in the sfa locus, and thus would not be able to produce SA and should not be able to grow
well in serum due to the inability to produce this siderophore common to staphylococcal
species (Table 3-3). Additionally, all isolates were PCR-positive for isd genes (PCR
across isdJ and isdK), indicating a presumptive ability to acquire heme-iron from
hemoglobin. All isolates also possess sir genes for SB acquisition (Table 3-3). Using
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Table 3-2: Similarity between iron-regulated proteins of Staphylococcus aureus and
Staphylococcus lugdunensis.
Protein	
  

%	
  ID/%	
  TS	
   Function	
  

FhuC	
  

86/95	
  

ATPase;	
  required	
  for	
  transport	
  of	
  
hydroxamates,	
  ferric-‐staphyloferrin	
  A,	
  ferric-‐
staphyloferrin	
  B	
  

FhuB	
  

72/85	
  

Permease;	
  specific	
  for	
  hydroxamates	
  

FhuG	
  

70/88	
  

Permease;	
  specific	
  for	
  hydroxamates	
  

	
  

	
  

	
  

SA	
  SstA	
  vs.	
  SL	
  SstA1	
  

80/92	
  

Permease;	
  specific	
  for	
  catechols	
  

SA	
  SstB	
  vs.	
  SL	
  SstB1	
  

72/88	
  

Permease;	
  specific	
  for	
  catechols	
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Table 3-3: Genes for iron acquisition in Staphylococcus lugdunensis clinical isolates.
sfa – genes for production of staphyloferrin A. isd – genes for heme acquisition from
hemoglobin. sir – genes for staphyloferrin B uptake. sst – genes for catecholamine
transport. - not hemolytic; + mild hemolysis 0.5-1.5mm; ++ moderate hemolysis 2.02.5mm, +++ more hemolysis >2.5mm after 24 hours at 37°C on sheep blood agar (BD
Diagnostics).
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primers within both sst loci and others that would amplify across the midsection of the
inexact, tandem duplicate sst loci, we found all isolates to contain both sst loci.
All clinical isolates grew poorly in C-TMS medium with 20% horse serum
(serum), and none were able to achieve a biomass of OD600>0.5. These isolates were able
to grow well in serum with addition of excess iron (100µM FeCl3), in which they attained
a biomass of OD600>1.0 (data not shown). Isolates had varying degrees of zones of
hemolysis on blood agar. In comparison to HKU09-01, few had greater hemolysis (3/26),
more had a similar level of hemolysis (7/26), most isolates were slightly less hemolytic
(11/26), and a fraction were not hemolytic (5/27). The non-hemolytic clinical isolates did
not exhibit hemolysis even during prolonged incubation (48 hours at 37°C). Previous
studies reported that approximately 5% of S. lugdunensis isolates were non-hemolytic,
whereas 19% of our isolates are non-hemolytic (55, 56).

3.3.3

Hemolytic clinical isolates are enhanced for growth in blood

The fact that we identified several non-hemolytic isolates in clinical manifestations led us
to speculate whether hemolysis plays an important role for S. lugdunensis growth in a
host environment. Several representative clinical isolates were assessed for growth in
iron-restricted media supplemented with fresh whole human blood. Using a low
concentration of blood, the hemolytic isolates, including HKU09-01, were able to achieve
a much greater bacterial density than the non-hemolytic isolates. Whereas hemolytic
isolates grew to a density of about 109 CFU/mL, non-hemolytic isolates, including
N920143, only grew to 108 CFU/mL under the same conditions (Figure 3-2A). The
growth difference is due to an inability of non-hemolytic isolates to obtain iron from
blood, as addition of excess iron to the media enhanced growth of non-hemolytic isolates
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Figure 3-2: Hemolytic Staphylococcus lugdunensis clinical isolates exhibit enhanced
growth in blood compared to non-hemolytic isolates. (A) Bacterial cultures were
grown in iron-restricted media supplemented with 0.001% whole human blood as a sole
iron source. (B) Excess ferric chloride was added to blood media to ascertain nonhemolytic isolate impairment for iron acquisition from blood. Data are the average of
three independent biological replicates, with error bars indicating standard error to the
mean.
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such to equal hemolytic isolate cell density (Figure 3-2B). An HKU09-01 isd mutant,
although hemolytic, grew as poorly as the non-hemolytic strains (Figure 3-2A). The
mutant was able to grow and exhibit hemolysis on blood agar plates (trypticase soy agar
base medium)(data not shown), however its growth was hindered when blood was the
sole source of iron, indicating that extracellular heme/hemoglobin are required for
growth. We conclude that hemolysis and subsequent heme acquisition via Isd are
required for optimal growth of S. lugdunensis in human blood.

3.3.4

fhuC is required for siderophore-mediated growth promotion
of S. lugdunensis

Siderophores contribute to microbial growth in low-iron conditions by appropriating
FeIII from host proteins such as transferrin and lactoferrin, and deliver it to
microorganisms for growth. It is also common for microorganisms to acquire
siderophores produced by heterologous organisms, a strategy that may be metabolically
favorable. This would be particularly advantageous for S. lugdunensis because it does not
produce a siderophore and, as such, this property would take on added importance to the
biology of this microbe. In previous work, we showed that S. lugdunensis was able to
acquire both S. aureus-produced SA and SB siderophores to promote its own growth in
serum (28), however its ability to use other siderophores has not yet been investigated.
Based on the presence of a canonical Fur box upstream of the fhu locus (Figure 3-3A),
we tested and confirmed that the fhu genes are iron-regulated (Figure 3-3B). This
suggests that in low-iron environments, S. lugdunensis may be able to use hydroxamate
siderophores as a source of iron. To test this, we created an in-frame fhuC deletion in S.
lugdunensis to determine whether this mutant would be debilitated for acquisition of
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Figure 3-3: Staphylococcus lugdunensis FhuC is iron-regulated and required for
uptake of hydroxamate and carboxylate siderophores. (A) Physical map of the ferrichydroxamate uptake genes in S. lugdunensis. The sequence in between (and including)
the black boxes underneath fhuC depict the chromosomal region deleted to produce a S.
lugdunensis in-frame fhuC deletion mutant. The promoter sequence for the operon is
shown, with the Fur box highlighted. (B) qPCR of fhu gene expression by wildtype S.
lugdunensis grown overnight in C-TMS (-Fe) or C-TMS with 100 µM FeCl3 (+Fe). Data
was normalized relative to rpoB expression, and gene expression was set relative to that
in C-TMS without added iron, set to 1 as the comparator. (C) Plate bioassays demonstrate
that a S. lugdunensis fhuC mutant is able to use catecholamine siderophores, but unable to
acquire hydroxamate-bound or staphyloferrin-bound iron. Water and ferric citrate were
used as negative and positive controls, respectively. Hydroxycarboxylates staphyloferrin
A (SA) and staphyloferrin B (SB) were administered as Staphylococcus aureus mutantderived culture supernatants as well as in-vitro synthesized compounds, with the
ΔsbnΔsfa strain unable to produce either siderophore. DFO; desferrioxamine B. Data are
the average of at least three independent biological replicates.
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various siderophores. In agreement with its predicted role in ferric hydroxamate uptake,
the fhuC mutant was unable to use a variety of hydroxamate siderophores as an iron
source, yet retained the ability to use catecholamine siderophores and citrate for means of
iron acquisition (Figure 3-3C). These fhuC-dependent phenotypes were complemented by
supplying fhuC in trans into the mutant strain. Of note, we also found that the fhuC
mutant was unable to utilize either SA or SB carboxylate siderophores (Figure 3-3C).
These results also mirror those seen in S. aureus, where FhuC is also required for uptake
of these endogenous siderophores (31, 37). Thus, FhuC plays an essential role in the
acquisition of multiple types of siderophores in several pathogenic species of
staphylococci.

3.3.5

S. lugdunensis sst genes are required for catecholamine
acquisition and growth in serum

Catecholamine hormones enhance growth of pathogenic bacteria in serum by mediating
iron release from transferrin (38, 40, 41, 57). Although catecholamines have little effect
on S. aureus growth unless SA and SB production is impaired, they can stimulate S.
epidermidis growth on transferrin (58, 59). Given the various growth-promoting effects
of catecholamines on several staphylococci, and that S. lugdunensis does not produce a
siderophore, we hypothesized that sst genes may contribute to iron acquisition by this
species. Analysis of sst promoter regions identified Fur boxes in both, indicating that
expression of sst loci would likely be iron-regulated (Figure 3-4A). qPCR revealed that
sst1 is highly upregulated in low-iron conditions compared to iron-replete conditions,
whereas sst2 gene expression was extremely low in either iron limited or iron-replete
conditions (Figure 3-4B). Moreover, using antisera generated against S. aureus SstD, we
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Figure 3-4: Staphylococcus lugdunensis Sst transporter expression. (A) Physical map
of putative ferric-catecholamine genes in S. lugdunensis. The tandemly duplicated loci
encode proteins where paralogs share ~70% identity (see Table 2). The sequence in
between (and including) the black boxes underneath sstA1-sstD2 depict the chromosomal
region deleted to produce a S. lugdunensis sst deletion mutant. The promoter sequences
for each gene set are shown, with Fur boxes highlighted. (B) qPCR of sst1 and sst2 gene
expression by S. lugdunensis grown overnight in C-TMS (-Fe) or C-TMS with 100 µM
FeCl3 (+Fe). Data were normalized relative to rpoB expression, and expression was set
relative to sst1 in C-TMS without added iron, set to 1 as the comparator. (C) Western blot
demonstrating iron-regulated expression of SstD1. Cultures were grown overnight in CTMS (-Fe) or C-TMS with addition of 100 µM FeCl3 (+Fe). Antisera raised against S.
aureus SstD was used to assay for S. lugdunensis SstD.
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demonstrated expression of one or both S. lugdunensis SstD proteins during iron-limited
growth (Figure 3-4C) (41).
To test the functionality of the sst genes in catecholamine-iron acquisition, we
constructed a mutant with both sst loci deleted, and assessed the growth of this mutant in
catecholamine-supplemented media. The sst mutant was defective for growth compared
to wildtype when grown in serum supplemented with the catecholamines dopamine, LDOPA, epinephrine, and norepinephrine (Figure 3-5). The mutant grew comparably to
wildtype in serum supplemented with DFO, owing to a functional Fhu transporter system
(see above). Supplementation with either the catechol siderophore precursor 2,3-DHBA
or the mammalian siderophore 2,5-DHBA did not promote S. lugdunensis growth. Thus,
sst genes in S. lugdunensis are required for catecholamine-iron transport.
In an attempt to determine the relative importance of sst1 and sst2, we sought to
create individual sst1 and sst2 deletion mutants. However, for reasons we were not able
to uncover, we were unable to create single sst-locus deletion mutants. We therefore
chose to complement the sst1-sst2 deletion mutant with vectors containing the individual
gene sets. The sst1 gene set complemented the catecholamine-dependent growth defect of
the mutant (Figure 3-5), confirming its role in the process. Unfortunately, although we
were able to clone the vector containing the sst2 gene set into E. coli and S. aureus, we
were unable to clone it into S. lugdunensis despite repeated attempts. S. lugdunensis
transformants always contained deletions within the sst2 region.
Since we were able to mobilize sst2 into S. aureus, we were therefore able to test
its role for catecholamine uptake in this organism. We cloned the vector, as well as that
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Figure 3-5: Staphylococcus lugdunensis sst1 is required for catecholamine-iron
uptake. Growth of S. lugdunensis Δsst was assessed compared to isogenic wildtype and
Δsst complemented with sst1 genes in trans (psst1), in C-TMS with 20% serum
supplemented with 50µM of each catechol compound indicated. Desferrioxamine B
(DFO), a hydroxamate, was used as a positive control. Data are the average of at least
three independent biological replicates.
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Figure 3-6: Staphylococcus lugdunensis sstA1-D1 is required for catecholamine
uptake by S. aureus sfa sbn sst. sst1 and sst2 loci from S. lugdunensis were introduced
into S. aureus sfa sbn sst and analyzed for growth in C-TMS with 20% serum,
supplemented with 50µM catecholamine hormones. S. aureus sfa sbn is depicted as the
WT strain, and all depicted strains contain sfa sbn mutations. Desferrioxamine B (DFO)
was used as a positive control. Data are the average of at least three independent
biological replicates.
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carrying sst1, into the S. aureus sfa sbn sst mutant (41). Vectors carrying sst1 and sst2
gene sets (psst1 and psst2, respectively) from S. lugdunensis were mobilized into S.
aureus sfa sbn sst and the strains were assessed for growth in serum supplemented with
catecholamines and compared to S. aureus sfa sbn (annotated as wildtype for simplicity).
S. aureus sfa sbn sst harboring psst1 grew much better than the vector control strain in
serum supplemented with epinephrine, norepinephrine, dopamine or L-DOPA (Figure 36). The S. aureus sfa sbn sst mutant harboring psst2 was impaired for growth with all
catecholamines, and grew similar to the vector control. All strains grew similarly when
serum was supplemented with DFO, indicating an inability to attain iron from transferrin
in the serum via catecholamines. Altogether these findings indicate that the Sst1
transporter is both necessary and sufficient for catecholamine-iron acquisition in S.
lugdunensis.

3.3.6

SstD proteins vary in catecholamine binding affinities

To determine differences in substrate-binding affinity, S. lugdunensis SstD1 and SstD2
were overexpressed and purified (41). Antisera raised against S. aureus SstD were able to
recognize both S. lugdunensis SstD1 and SstD2 purified proteins (Figure 3-7A). The
three proteins were analyzed for substrate binding via intrinsic tryptophan fluorescence
quenching. Bovine serum albumin fluorescence was not quenched with any tested
ligands, serving as a protein negative control. The fluorescence of all three SstD proteins
was quenched with added catecholamines, but not DFO (Figure 3-7B). S. aureus SstD
was determined to bind each respective catecholamine with a similar dissociation
constant as to a previous report (Figure 3-7C) (41). S. lugdunensis SstD1 was found to
bind each of the catecholamine stress hormones analyzed, and the catechol(amine)
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Figure 3-7: Substrate-binding dynamics of Staphylococcus aureus SstD and
Staphylococcus lugdunensis SstD1 and SstD2. (A) Coomassie (top panel) and Western
blot (bottom panel) of overexpressed and purified S. aureus (SA) and S. lugdunensis (SL)
SstD homologs, cloned without lipobox motifs and overexpressed in E. coli. Proteins
were assayed for using anti-S. aureus SstD antiserum. (B) Fluorescence quenching was
used to determine binding affinity of SstD homologs for ferrated catecholamine
hormones. (C) Table of KD values for SstD-ferric catecholamine complexes. Data are the
average of at least three independent biological replicates, with error bars representing
the standard error to the mean.
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siderophore salmochelin, with greater affinity than the S. aureus homolog (Figure 3-7C).
Dissociation constants for S. aureus SstD binding of ligands were 2-3x higher than that of
S. lugdunensis SstD1. Both proteins had the least affinity for L-DOPA (other than DFO).
S. lugdunensis SstD2 also bound these substrates, albeit more poorly than either of the
other two proteins. Dissociation constants for SstD2 were over 4x greater than those of S.
lugdunensis SstD1 for epinephrine, norepinephrine, dopamine, and salmochelin (Figure
3-7C). Consequently, S. lugdunensis SstD2 bound all catecholamine hormones and
salmochelin with less affinity than either S. lugdunensis SstD1 or S. aureus SstD.

3.3.7

Role of fhu and sst in iron-restricted growth of S.
lugdunensis

We next considered the possibility that the fhu and/or sst genes play a role in growth
under iron starvation conditions, even in the absence of hydroxamates or catecholamines,
respectively. Spot plating revealed that on TSB, there was no noticeable difference in
growth between wildtype and fhuC and sst mutants (Figure 3-8A). When spotted on ironrestricted minimal salts medium (TMS), we noticed a reproducible growth delay for the
sst mutant, a phenotype that was complementable with introduction of the sst1 locus in
trans (Figure 3-8A). We next coupled the fhuC and sst deletions together into one strain.
This mutant, interestingly, was growth impaired not only on TMS minimal medium, but
also TSB rich medium. This growth impairment was complemented by introduction of
either fhuC or sst1 in trans (Figure 3-8B). On TMS medium, the double mutant was
severely growth attenuated (Figure 3-8B). Together, these data demonstrate that both the
fhu and the sst1 loci play a role in vital nutrient acquisition for this species, both in the
presence and absence of hydroxamates or catecholamines, respectively.
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Figure 3-8: Staphylococcus lugdunensis Sst1 and FhuC contribute to growth in
absence of catecholamines and hydroxamates. (A) Growth of ΔfhuC and Δsst single
gene set-deletion mutants was compared to wildtype and the Δsst mutant complemented
with sst1 genes (psst1), on rich media (TSB) and minimal media (TMS). (B) Growth of
the ΔfhuC Δsst double mutant was compared to wildtype and the ΔfhuC Δsst double
mutant complemented with either fhuC (pfhuC) or the sst1 gene set (psst1). One
experiment that is representative of consistent results from several biological replicates is
shown.
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3.3.8

Iron acquisition through Isd, FhuC and Sst contribute to host
colonization and virulence

There is no model for S. lugdunensis systemic infection, with only two reports of animal
infection available (to our knowledge). A catheter-induced rat endocarditis model showed
that surface-anchored proteins, through Sortase A (SrtA), are required for S. lugdunensis
pathogenesis (48). A recent article detailed a similar means to induce endocarditis in
mice, in which induced inflammation was required to promote initial adherence of
stationary-phase S. lugdunensis to aortic valve leaflets through von Willebrand factor
(vWF) (60). In either infection, SrtA and vWF deficiency led to decreased bacteria in
endocardial vegetations. Here, we modeled a S. lugdunensis systemic infection, without
the use of a catheter. All mice survive the duration of the experiment. S. lugdunensis were
administered to mice via tail-vein, after which infection was allowed to proceed over the
course of several days. We noted that S. lugdunensis-infected mice do not become as sick
as S. aureus-infected mice, even with greater CFU administration (61, 62). Nevertheless,
the pathogenesis of S. lugdunensis murine infection was more similar to that of S. aureus
infection rather than S. epidermidis infection, wherein we administer fewer bacteria
which persist for a longer duration (63, 64).
Coinciding with previous studies of S. lugdunensis rodent infection (48, 60), our
infected mice did not exhibit overt sickness relative to S. aureus-infected rodents (61,
62). To assess the role of the aforementioned iron acquisition pathways for colonization
and virulence of S. lugdunensis, we combined isd, fhuC and sst mutations into one strain.
Wildtype S. lugdunensis-infected mice lost significantly more weight than mice infected
with a isd fhuC sst mutant during 4-6 days post-infection (Figure 3-9A). Mutant-infected
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Figure 3-9: Iron acquisition through Isd, FhuC and Sst contributes to
Staphylococcus lugdunensis pathogenesis. Female BALB/c mice were infected
systemically with 2-3x107 CFU S. lugdunensis wildtype or an isogenic isd fhuC sst
mutant. (A) Animal weight change was monitored over a period of 6 days, wherein
animals were sacrificed for quantification of bacterial burden. (B) Bacterial load in the
kidneys of infected mice was measured at various time points coinciding with weight
change differences between the infection groups. The mean is depicted by a horizontal
bar, with error bars corresponding to standard error to the mean for each group. Statistical
analyses were performed using an unpaired Student’s t-test. The limit of detection is the
y-axis value at the origin.
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mice did not lose weight over the course of the experiment. The isd fhuC sst mutant was
significantly impaired in its ability to colonize murine kidneys at 3 days post-infection
compared to wildtype S. lugdunensis. However, after 4 days, the decreased bacterial
burden was trending towards significance, and at 6 days, the bacterial burden was
equivalent to wildtype. Therefore, it appears that the mutant is able to keep reproducing,
presumably at a slower rate than wildtype, until the bacterial burden reaches wildtype
level and plateaus 6 days post-infection (Figure 3-9B). Strikingly, there was a disconnect
between weight loss and bacterial burden; at 3 days post-infection, there was no
significant difference in weight loss, even though mice challenged with wildtype bacteria
exhibited a significantly greater bacterial burden, while at 6 days post-infection, there
was no difference in bacterial burden, in spite of the significantly greater weight loss
displayed by mice challenged with wildtype S. lugdunensis. Given these findings, we
conclude that these iron acquisition mechanisms impact the ability of S. lugdunensis to
colonize host organs, and, based on weight loss, impact health.

3.4 Discussion
S. lugdunensis is capable to thrive in diverse infection niches within the human host and
is able to cause unusually aggressive infections, which contrasts infections typical of
CoNS. S. lugdunensis is unusual amongst the staphylococci in that it does not produce a
siderophore. Accordingly, we showed that it is severely growth attenuated in animal
serum unless it is supplemented with factors to compromise the iron-withholding
capacity of transferrin (28). In this study, we have identified a single gene, fhuC, that is
critical for iron acquisition from SA and SB (produced by other species of staphylococci),
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as well as siderophores produced by fungi and Enterobacteriaceae (ie. ferrichrome,
coprogen, aerobactin).
Catecholamine stress hormones are able to interact with and reduce iron within
transferrin and other iron-withholding glycoproteins to render it available for intruding
pathogens. In addition to siderophore acquisition, we found that S. lugdunensis is capable
of catecholamine transport, which we have attributed to the sst1 locus. S. lugdunensis is
unique among staphylococci to carry duplicate sst regions, which was evident in all of
our assessed clinical isolates (25, 26). This latter observation is in agreement with a
recent study supporting S. lugdunensis as a clonal species (65).
Interestingly, S. lugdunensis SstD2, compared to the other SstD homologs, has
inferior affinity for catecholamine substrates. Of interest, although we identified a Fur
box in the promoter region of sst2, we were unable to identify a growth medium or
conditions that resulted in expression of this locus. At present, it is unknown what
purpose sst2 serves for S. lugdunensis. Unlikely to function for inferior, redundant
catecholamine transport, sst2 may serve to transport a vitamin (ie. thiamine or folic acid),
many of which contain similar structures to catechol. With the inability to produce a
siderophore, S. lugdunensis appears able to adapt well in the presence of catecholamine
xenosiderophores and stress hormones through a transporter with greater affinity than the
S. aureus ortholog. It is noteworthy that for the S. lugdunensis Isd system, IsdB was
found to bind hemoglobin with greater affinity than S. aureus IsdB (27, 66). Being
endowed with seemingly fewer iron-acquisition strategies may have necessitated
evolution of optimized iron-compound transport by S. lugdunensis, which may be
advantageous to colonization. Large reservoirs of plasma catecholamines surround
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mesenteric organs, kidneys and the liver in venous and arterial circuitry, and levels may
spike in individuals undergoing therapeutic or recreational drug use (67). Conditions
promoting elevated serum stress hormones are likely to enhance S. lugdunensis growth
during infection. Furthermore, stress hormones have immunoregulatory roles and may
alter immune cell function to further favor infection conditions (68, 69). The interplay
between the effects of hormones on immune function and infection merits future
investigation.
Another interesting finding from this study is that FhuC and Sst1 contribute to
vital nutrient acquisition even in the absence of known substrates (Figure 3-8). This begs
the question, in what form is iron coming into the cell? Is it complexed to an unknown
chelating molecule? Are amino acids, short peptides, or vitamins able to coordinate iron
to some degree? We are currently investigating these questions in more detail. It is
interesting that these two transporters have evolved novel functions in addition to those
hypothesized. S. lugdunensis IsdC, although necessary for heme acquisition, is also
critical for biofilm formation (70). With seemingly fewer virulence determinants than S.
aureus, S. lugdunensis has evolved for its expressed factors to not only bind substrates
with greater affinity than homologous proteins in other organisms, but also to have those
same transporters elicit additional functions.
Animal models for experimental S. lugdunensis catheter-induced endocarditis are
published (48, 60). Both of these require surgical catheter insertion past the rodent aortic
valve. However, many reports describe cases of S. lugdunensis native valve endocarditis
following surgical procedures or skin trauma in dissociate regions of the body, indicating
an ability to colonize internal organs in absence of surgical prosthesis insertion and
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predisposing risk factors (9, 12–14). Therefore, organs other than the heart should not be
disregarded, as these serve as not only sites of infection but also contribute as reservoirs
for dissemination. In the systemic infection model used in this study, we do not typically
recover S. lugdunensis CFU from murine hearts. Induced inflammation of the heart
endothelial vasculature may be necessary to stimulate S. lugdunensis heart colonization
(60). Nevertheless, we are able to consistently recover bacteria from the kidneys, and
occasionally in smaller numbers from the liver and lungs. A mutant impaired for
acquisition of heme, siderophores and catecholamine stress hormones is debilitated for
growth in murine kidneys at early stages of infection, yet is still eventually capable of
colonizing kidneys. Interestingly, despite an abundance of bacteria in the kidneys, mice
are generally in good relative health. Albeit showing discomfort, sickness is in stark
contrast to mice infected with S. aureus. Still, S. lugdunensis-infected mice lose weight,
and the bacteria are able to persist longer than S. epidermidis in a similar model, giving
credence to the notion that S. lugdunensis has elevated virulence compared to other CoNS
(63, 64). Difference in weight loss between wildtype and mutant-infected mice does not
coincide with differences in bacterial burden in the kidneys. These findings are
unexpected, yet indicate that the surreptitious S. lugdunensis may reside quite amiably
within host organs such as the kidneys yet not cause overt morbidity. Persistence may
enhance dissemination to other organs via renal circulation. It may be that S. lugdunensis
is also present in yet undetermined murine organs as well, or the mutant may elicit
different pathology in kidneys. The genome of S. lugdunensis indicates an absence of
many well-characterized S. aureus immune-evasion and toxin encoding genes. The less
aggressive course of infection for S. lugdunensis as compared to S. aureus-infected mice
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is undoubtedly attributed to these genetic differences, whereas the more aggressive
course of infection for S. lugdunensis compared to other CoNS, such as S. epidermidis,
largely remains to be elucidated. The less aggressive disease phenotype of systemic S.
lugdunensis infection may allow the pathogen to remain undetected by the host immune
system for a longer period of time, compared to S. aureus, providing greater capability
for dissemination and persistence until (host) environmental factors become conducive to
promote the severe pathogenesis S. lugdunensis is capable of causing.
It is striking that a proportion of clinical isolates are not hemolytic, yet
nonetheless bear genes for procurement of heme as well as other iron sources. It may be
that non-hemolytic isolates are preferentially found in co-infection, in specific host
niches, or have different iron source preferences than hemolytic isolates. The relationship
between hemolytic potential and iron source preference merits further investigation, as
non-hemolytic isolates may thrive with non-heme iron sources compared to hemolytic
isolates, which clearly thrive in comparison in the presence of human blood.
Alternatively, hemolytic isolates may cause a more aggressive disease progression or be
more fit for pathogenesis than non-hemolytic isolates during systemic infection.
In conclusion, we have identified the genetic means for S. lugdunensis to procure
an assortment of diverse siderophores and catecholamine hormones through FhuC and
Sst1, respectively, and shown them, along with Isd, to play a significant role in
colonization and virulence. Other yet unidentified iron acquisition mechanisms must also
be functional in the mammalian host and identifying these is a priority research area.
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Chapter 4
Discussion, conclusions and future directions
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4.1 General overview
There exists limited molecular detail of S. lugdunensis genetic factors contributing to
virulence. We, and others, continue to try to understand more about the lifestyle of this
enigmatic pathogen. In this thesis, I have described several means by which S.
lugdunensis acquires iron, including mechanisms for transport of staphyloferrin A (SA),
staphyloferrin B (SB), hydroxamates, catecholamines and heme (1).

4.1.1

Defective staphyloferrin A biosynthesis

We have shown that S. lugdunensis grows poorly in animal serum, owing to its inability
to produce a siderophore. Exogenously supplied siderophores or other iron sources
promote growth in serum, indicating a parasitic predisposition to obtain transferrin-iron
via environmentally scavenged metabolites. Despite this, the deletion in the SA
biosynthetic locus has been retained across S. lugdunensis isolates, indicating it may be
metabolically favourable for the species to divert precursor molecules that would have
been used for SA biosynthesis for other uses, while simply feeding on xenosiderophores.
Given the nature of cohabitation on skin with other staphylococci, which produce SA (SA
is made by the majority of CoNS, including S. epidermidis) and SB, it is fitting to
consider either of these compounds may be in abundance where S. lugdunensis is
typically found (2–5). Recent insight into S. aureus metabolism has found that the Kreb’s
cycle-associated citrate synthase is required for synthesis of SA, but not SB. The ironsparing response decreases Kreb’s cycle activity under iron limitation, and millimolar
glucose concentrations inhibit SA biosynthesis (6, 7). Nevertheless, SA production by S.
aureus is required for causing pathogenesis during murine subcutaneous infection (8).
These data, together with the predominance of SA production among skin colonizing
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staphylococci, suggests a likelihood that SA is abundantly expressed and found on
mammalian skin (9). It is therefore not surprising that some organisms, such as S.
lugdunensis, may inhabit this niche while usurping this metabolite produced by other
microbes.

4.1.2

Staphyloferrin transport

No remnants of SB biosynthesis genes are found in the S. lugdunensis genome, yet sir
genes are present for transport of SB, in addition to hts genes for SA uptake. Both hts and
sir loci have Fur boxes in their promoter regions and expression of both is iron-regulated.
Genetic manipulation of S. lugdunensis, including generating mutations such to remove
hts and sir genes, proved to be problematic. While means to genetically manipulate S.
aureus are well established, there is a lack of detail for similar practices in other
staphylococci (10, 11). Different cell wall architecture and genetic barriers hinder
horizontal gene transfer, including intra-genus exchange of genetic material. Importantly,
the work presented in this thesis and a limited number of other groups, has managed to
overcome some of these limitations through development of tools and optimized
processes to better study S. lugdunensis, which should be of use to other scientists as
well, as the pathogen continues to gain notoriety in the clinic. After literature review and
optimized procedures, we were able to obtain S. lugdunensis vector transformants and
generate genetic deletion mutants. Being able to genetically manipulate S. lugdunensis
allows us to determine the function and biological relevance of genes of interest. Analysis
of hts and sir locus mutants showed that these are indeed required for acquisition of SA
and SB, respectively, by S. lugdunensis. Polymicrobial infections involving S.
lugdunensis also commonly include other staphylococci such as S. epidermidis and S.
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aureus (12). When grown together in serum, S. lugdunensis is able to pirate SA and SB
synthesized by S. aureus to promote its own growth. A S. lugdunensis Δhts Δsir mutant is
impaired for growth in the same conditions, supporting our notions that cohabiting the
same microenvironment with siderophore producers augments S. lugdunensis growth. SA
biosynthesis is inhibited at blood-glucose concentrations, and SB is likely the more
important of the two siderophores for internal infection of the host. S. lugdunensis is one
of few staphylococcal species to encode the SB transporter, which may be relevant for
persistence in host organs.

4.1.3

Heme acquisition

S. lugdunensis is unique among coagulase-negative staphylococci (CoNS) to encode the
Isd pathway of heme-iron acquisition, albeit with several distinct proteins. IsdJ and IsdK
have 2 and 1 NEAT domains, respectively, and are found in both membrane and
supernatant fractions. The biological function of these potential hemophores, and
interaction with other Isd proteins, has not been investigated, although both are able to
bind heme but not hemoglobin (13). An Isd-associated autolysin (IsdP) alters processing
and attachment of the heme-conduit protein IsdC to peptidoglycan (14). IsdC in S.
lugdunensis is also distinct in its role for biofilm formation in this species (15). Surfaceexposed IsdB is unable to bind mouse hemoglobin, but binds human hemoglobin with
greater affinity than the S. aureus ortholog (13, 16). S. lugdunensis IsdJ is homologous to
S. aureus IsdA, and both confer resistance to bactericidal lipids in addition to their
respective roles in heme acquisition. The Isd system supports S. lugdunensis growth with
low nanomolar concentrations of heme/hemoglobin, serving a high-affinity means to
procure heme-iron in physiological conditions. Once infection has been established and
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host cell lysis (including hemolysis) has taken place, conditions become nonphysiological and heme concentration is increased. It is believed that other, non-Isd
means of heme acquisition become more relevant in these conditions, as isd mutants are
still able to use heme at greater concentrations. The mutant is able to use heme at lower
concentrations in acidified media (same media used in heme/hemoglobin growth
experiments in chapter 2, set to pH 6.4), and grows to more appreciable biomass sooner
as well (data not shown). This growth is not seen with equimolar FeSO4 in place of heme,
indicating the metal chelator (EDDHA) and heme in the media have not degraded (data
not shown). An acidic microenvironment may be caused by accumulation of metabolic
end products or immune defense, which for staphylococci may be an indication of harsh
conditions. These results may indicate that environmental pH (such as that commonly
found in an abscess environment) has an effect on iron acquisition by staphylococci. A
somewhat similar phenomenon affects siderophore acquisition by Vibrio
parahaemolyticus, which upregulates enterobactin acquisition in response to alkaline pH
(17). S. lugdunensis, like S. aureus and V. parahaemolyticus, is hemolytic and would
likely need to adapt once substantial tissue damage has occurred. One may speculate that
at high heme concentrations, high-affinity heme transport could cause heme
internalization too quickly for proper mobilization/organization, such to cause toxicity
(via free internal heme/iron, yet to be bound), and lower affinity heme uptake strategies
may be necessary in addition to heme detoxification systems to mitigate heme toxicity.

4.1.4

Siderophore and catecholamine uptake

In addition to heme acquisition, S. lugdunensis uses the homodimeric FhuC ATPase to
acquire siderophores. The fhuCBG locus is upregulated in response to iron limitation, and
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although FhuBG comprise the permease component required for hydroxamate uptake, the
FhuC ATPase is more promiscuous in its binding partners and also associates with
HtsBC and SirBC. S. lugdunensis, much like S. aureus, relies on FhuC to acquire several
different hydroxamate and carboxylate siderophores. In contrast to S. aureus, we
identified two loci in S. lugdunensis that we presumed may be involved in catecholate
acquisition. Paralogous proteins share approximately 70% sequence identity but little
similarity in their regulation and substrate affinity. Sst1 is responsible for catecholamine
acquisition as this locus complemented a sst mutant growth defect in presence of the
catecholamine stress hormones epinephrine, norepinephrine, dopamine and L-DOPA.
This transporter does not acquire all catecholates, as 2,3-DHBA and 2,5-DHBA could not
be used as sources of iron. Interestingly, common catechol-type siderophores such as
enterobactin, bacillibactin and salmochelin have catecholamine iron-coordinating
moieties. The amine group in place of a carboxylic acid appears to be important for
substrate recognition by SstD. In keeping with this, S. aureus SstD and S. lugdunensis
SstD1, both of which bind and transport catecholamine-iron, have the least affinity of
analyzed substrates for L-DOPA, which bears both amine and carboxylic acid moieties.
The other analyzed hormones have only amine (dopamine), or amine and alcohol groups
(epinephrine, norepinephrine) and are bound with greater affinity.

4.1.5

S. lugdunensis transporters are superior in function, and
exhibit additional biological purposes compared to
homologous systems in other organisms

At least two iron-acquisition mechanisms (Isd and Sst1) of S. lugdunensis have greater
affinity for substrates than homologous systems in other organisms, namely S. aureus.
The same may be true of other transporters, including Hts and Sir as well (although we
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currently have no data to support this claim), giving the bacterium more of a competitive
advantage. If S. lugdunensis has evolved more sophisticated/professional iron acquisition
systems than other bacteria, it could use iron sources at lower concentrations than other
organisms, including siderophore-producing microbes. Additionally, the lack of
traditional virulence factors may be offset by multifunctional expressed factors that
contribute to multiple different biological functions. Sst1 and FhuC impact S. lugdunensis
growth in the absence of catecholamines and hydroxamates (or siderophores). On
minimal media (TMS) the sst mutant is impaired for growth, and on rich media (TSB), a
fhuC sst mutant is impaired for growth. The double mutant is even more-so attenuated on
minimal media. Although the fhuC mutation has little impact on S. lugdunensis growth
on these media, the combination of fhuC and sst mutations renders the strain much more
attenuated for growth than the sst mutation alone. These findings are unexpected and
signify that these transporters are more important to the inherent biology of this organism
than previously thought. It may be that FhuC is involved in transport of other iron
sources, including free iron, and Sst1 may transport catecholamine-like compounds that
are able to chelate iron to some degree. The thought here being that TSB is iron-rich and
should supply the bacterium such to limit expression of iron-regulated genes, unless iron
cannot be taken up through FhuC, and iron-acquisition genes become expressed. In this
case, Sst1 would be expressed and may overcome this deficiency. Both FhuC and Sst1
transporters are expressed in minimal media, however other nutrients are relatively rich
and one or more of these may be additional substrates of Sst1. In addition to the multiple
functions of certain S. lugdunensis Isd proteins, these two transporters also appear to
exhibit novel functionality.
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4.1.6

Live animal infection

During the course of this study, two S. lugdunensis animal infections were published,
both being induced endocarditis models in rodents, and only sortase A was identified as a
virulence determinant in the host (10, 18). We developed murine subcutaneous and
systemic infection models in which we could recover viable bacteria from mouse organs.
In a systemic murine infection model, the iron-acquisition systems we characterized in
vitro did indeed contribute to the ability of S. lugdunensis to colonize host tissue and
cause virulence in vivo. Although S. lugdunensis Isd is unable to bind mouse hemoglobin,
other Isd proteins are involved in heme uptake, and may still be relevant in this infection
model. FhuC and Sst are directed towards procurement of several prokaryote-produced
and host-produced iron-binding compounds, respectively. A isd fhuC sst mutant is
significantly debilitated for growth at early stages of colonization/infection, however is
not eliminated from the host, and persists. The mutant is hindered for causing sickness, as
mutant-infected mice do not lose weight as wildtype S. lugdunensis-infected mice do.
Systemically infected mice do not typically exhibit S. lugdunensis heart valve
colonization, although there is some evidence indicating that endothelial vasculature
activation, through inflammation or damage, is required for adhesion, mediated by von
Willebrand factor. Organs other than the heart contribute as not only infection sites but
also reservoirs for dissemination, and should not be overlooked. A model of systemic
infection with induced heart vessel inflammation may better mimic clinical courses of S.
lugdunensis infective endocarditis.
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4.1.7

Hemolysis

During the course of this research we were fortunate enough to obtain a collection of S.
lugdunensis clinical isolates from London Health Sciences Centre - Victoria Hospital
(London, Ontario, Canada). All assessed isolates grow poorly in serum, unless the serum
is supplemented with exogenous iron sources, and all isolates contain genes for SB, heme
and catecholamine uptake. Many of these clinical isolates are non-hemolytic, and these
isolates are at a disadvantage for growth in human blood. Non-hemolytic isolates may be
favoured in certain types of infection, polymicrobial infections, or they may have
different nutrient preferences. In addition to the presence of a membrane-bound clumping
factor, the varying hemolysis profiles add further doubt to clinical identification
representing the true burden of S. lugdunensis infection.

4.2 Conclusions
Although S. lugdunensis does not produce a siderophore, it is able to acquire
siderophores of all major types, in addition to heme-iron from human hemoproteins.
Hydroxamates and/or hydroxycarboxylate xenosiderophores may be bound by receptors
with greater affinity over that of competing organisms, such is true for heme/hemoglobin
and catecholamines.
Non-hemolytic clinical isolates are impaired for iron acquisition from blood,
compared to hemolytic isolates. Most host-iron is coordinated in hemoproteins within red
blood cells. The frequency of non-hemolytic S. lugdunensis strains still capable of
causing infection warrants research into possible reasons as to how these isolates are able
to persist and cause disease.
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The transporters of S. lugdunensis are multifunctional, and although the bacterium
may seemingly encode fewer traditional virulence factors than other nefarious pathogens,
each of those expressed is able to accomplish additional biological functions for the
pathogen, compared to homologous systems in other bacteria. This is true for Isd, FhuC
and Sst1, with each of these transporters having functional pleiotropy important for the
bacterium in various environmental conditions.

4.3 Significance of this study
Little is known about S. lugdunensis biology, and the molecular characterization of this
species is in its infancy. This study builds on previous work by others describing several
S. lugdunensis Isd proteins, adding to the comprehensiveness of this pathways description
(13, 19). We are first to characterize multiple strategies of this organism to acquire a vital
nutrient, and show that specific nutrient transporters contribute to host colonization and
virulence. Several of these iron-acquisition mechanisms were shown to be important for
novel functions in addition to those of homologous systems in other organisms.
In combination with discoveries by other groups, the findings of this study enable
us to create a pictorial description of transport processes involving S. lugdunensis iron
acquisition pathways (Figure 4-1). Although the majority of host-iron is kept within heme
in hemoproteins, the vast majority of which reside in cells, S. lugdunensis has means to
lyse these cells, extract heme from hemoglobin and funnel it into the bacterial cytoplasm
for degradation. The absolute requirement of this precious nutrient necessitates successful
pathogens elaborate many strategies to attain it from a variety of sources. Although a
comparably smaller iron pool, transferrin-iron is labile, and along with other
glycoproteins these iron sources comprise another important pool of nutrients.

211

Figure 4-1: Schematic of Staphylococcus lugdunensis transporters involved in
nutrient acquisition. Isd proteins acquire heme (Hm)-iron(+Fe) from hemoglobin (Hb),
are important for biofilm formation (IsdC) and protection from bactericidal lipids (IsdJ).
Autolysin IsdP remodels peptidoglycan to facilitate IsdC movement. Staphyloferrin A
and B carboxylate siderophores are transported through Hts and Sir, respectively.
Hydroxamates are acquired through Fhu, which uses the FhuC ATPase for acquisition of
these, as well as carboxylate siderophores. Catecholamines are transported via Sst1. FhuC
and Sst1 are involved in acquisition of other nutrients as well, which is currently being
examined in more detail.
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The many (seemingly) functionally redundant iron uptake strategies are expressed
and required in different conditions. Obviously, they are likely to be expressed in lowiron conditions when the bacterium requires iron, however other mechanisms of
regulation must also exist. Although the preferred iron source for S. aureus is heme, and
siderophore biosynthesis is downregulated in the presence of heme, the iron source
preference of S. lugdunensis is undetermined. Ever-changing microenvironments
surrounding bacteria necessitate the ability of pathogens to adapt to new conditions,
which may require other, more metabolically favourable means to acquire host nutrients.
The host elicits functions to maintain homeostasis, while pathogens circumvent these to
obtain host nutrients, producing different metabolite concentrations from/in various areas
of tissue. It is likely that each iron-compound transporter is required for optimal
exploitation of a specific niche. The iron acquisition strategies uncovered here are
required for optimal exploitation of internal host organs (kidneys), and aid in the
organisms ability to cause disease.

4.4 Areas of future investigation
4.4.1

Siderophore-iron removal

The intracellular fate of siderophores in staphylococci remain largely unknown. In S.
aureus, oxidoreductase IruO and nitroreductase NtrA aid in iron removal from heme.
IruO also facilitates iron release from ferric-desferrioxamine (hydroxamate siderophore),
whereas NtrA from ferric-SA (20). S. lugdunensis encodes homologs to both of these in
its genome. The IruO homolog (SLGD_00660) shares 68% identity and 84% similarity,
whereas the NtrA homolog (SLGD_02019) shares 72% identity and 85% similarity.
These may have similar or distinct functions compared to the S. aureus homologs. Ferric-
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SB is also likely to undergo reduction to release iron, although there is no proposed
reductase for this process as of yet. There is a greater likelihood of iron release from
hydroxamate and carboxylate siderophores via reduction as opposed to degradation,
which is more geared towards catecholamines which bind iron with greater affinity (21–
23). Catecholamine-iron release also remains uninvestigated in staphylococci, and may
be driven by a hydrolytic enzyme such as an esterase or amidase.

4.4.2

Biological differences between FhuC and Sst1

Characterization of additional substrates transported by FhuC and Sst1 is underway. This
information will aid in uncovering the importance of the Sst system encoding its own
ATPase. Several siderophore-acquisition transporters (Hts, Sir and Fhu; SA, SB and
hydroxamate uptake), and possibly other iron-source transporters, use FhuC for energy to
import iron-containing substrates. An ATPase associated with the Isd system remains to
be elucidated, although heme is recognized by S. aureus (and possibly other
staphylococci) in a different manner than other iron sources, so it is not surprising for the
Isd transporter to use a different ATPase. Sst transports catecholamine siderophores and
stress hormones. These siderophores may require degradative means to release iron,
which contrasts from the other siderophores, however this is little motive to reason
requirement of another ATPase specific for their transport. There must be other
conditions facilitating differential expression of fhu and sst, and we find that Sst1 (and
also FhuC) in S. lugdunensis transports more substrates than originally believed, and may
be expressed to obtain these novel substrates. Additionally, the effects of catecholamine
hormones on staphylococcal gene expression may be an exciting new research
opportunity. It has been shown that catecholamines such as norepinephrine, epinephrine
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and dopamine are sensed by adrenergic receptors (QseCE two-component system) on
enteric microbes including enterohemorrhagic E. coli and Citrobacter rodentium to
regulate virulence factor expression (24, 25). A similar phenomenon occurs in Vibrio
species and may be widespread to include Gram-positive bacteria as well (26, 27). The
fate of staphylococcal internalized catecholamine hormones remains unknown. It is
obvious that there are biological differences between Sst and the other siderophore
acquisition systems, which may be of importance on a global scale.

4.4.3

Characterize hemolysis

As elaborated in Chapters 1 and 3, factors affecting S. lugdunensis hemolysis are poorly
understood. Although genes for hemolysins are present in all S. lugdunensis isolates, a
fraction remain non-hemolytic. Is this due to a regulatory defect – possible repression of
hemolysin genes, or overexpression of (metallo)protease to degrade secreted hemolysins?
Furthermore, which hemolysin gene/s are responsible for lysing cells? The three
suspected are β-hemolysin (SLGD_00006), hemolysin III (SLGD_00847) and the
SLUSH peptides (SLGD_00440 – SLGD_00442). Although non-hemolytic strains are
impaired for growth with blood as a sole source of iron in vitro, are they impaired for
growth in vivo, compared to hemolytic isolates? It is possible that non-hemolytic isolates
have a differential preference towards iron sources other than heme, or infection
conditions favour losing hemolytic capability.

4.4.4

Improved animal models

Whereas S. lugdunensis disease severity mirrors or surpasses that of S. aureus in the
clinic, it is inferior in causing disease in mice. We have developed subcutaneous and
systemic S. lugdunensis murine infection models in which we recover great quantities of
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viable bacteria from subcutaneous lesions, and kidneys. Presence of bacteria in liver and
lungs varies over the course of our systemic infection (3-6 days), indicating that they may
be cleared faster in these organs. It is also possible that the liver reservoir of S.
lugdunensis are primarily sequestered by Kupffer cells, prior to dissemination to other
organs (28). Heart endothelial activation, combined with systemic infection would be an
interesting model to assess virulence factors that may be associated with S. lugdunensis
heart colonization, persistence and virulence. It would be interesting to evaluate the
herein discovered iron acquisition strategies for S. lugdunensis fitness in other host
niches.
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